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MODULATION OF ANGIOGENESIS

ity in a subject are provided. The methods include administering to the subject a compound that regulates the bioavailability or biological activity ofVEGF or PlGF by modulating
the availability of a VEGF or PLGF inactivating agent. The
administering is sufficient to treat or prevent the condition in
the subject.
The inactivating agent generally forms a complex with
VEGF or PlGF by binding to VEGF or PlGF. A compound
provided herein can modulate VEGF or PlGF bioavailability
or biological activity by preventing, inhibiting or disrupting
the formation of the complex. In one aspect, this is accomplished by decreasing the amount of the agent, such as by
regulating the expression of the agent. In other aspects, preventing, inhibiting or disrupting the formation of the complex
includes binding of the compound with complexed or uncomplexed inactivating agent. VEGF includes VEGF-A, VEGFB, VEGF-C andVEGF-DandPlGF includes PlGF-1 or PlGF2.
In one aspect, the agent comprises a VEGFR1, VEGFR2 or
VEGFR3 polypeptide. Exemplary VEGFR1 polypeptides are
encoded by the fms-like tyrosine kinase (Flt-1) gene. Exemplary polypeptides include isoforms such as sflt-1 and mbflt-

CROSS REFERENCE TO RELATED
APPLICATIONS
This application claims priority to U.S. Provisional Application Ser. No. 60/764,269 filed Feb. 1, 2006, the disclosure
of which is incorporated herein by reference.
TECHNICAL FIELD
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This invention relates to compounds, compositions, and
methods for the treatment of traits, diseases and conditions
that respond to the modulation of angiogenic growth factor
bioavailability or biological activity.

15

BACKGROUND
The formation of new blood vessels either from differentiating endothelial cells during embryonic development (vasculogenesis) or from pre-existing vessels during adult life
(angiogenesis) is an essential feature of organ development,
reproduction, and wound healing in higher organisms. Angiogenesis is also necessary for certain pathological processes
including tumorigenesis and retinopathy. While several
growth factors can stimulate angiogenesis vascular endothelial growth factor (VEGF) is a potent angiogenic factor that
acts via the endothelial cell-specific receptor tyrosine kinases
fms-like tyrosine kinase (Fltl) and fetal liver kinase (Flk1)
(also designated KDR). These two VEGF receptors and a
third orphan receptor, Flt4 constitute a subfamily of class III
receptor tyrosine kinases that contain seven extracellular
immunoglobulin-like domains and a split intracellular
tyrosine kinase domain. These three receptors have 31-36%
amino acid identity in their extracellular ligand-binding
domains.
VEGF is a homodimeric, cysteine-rich protein that can
occur in at least four forms due to alternative splicing of its
mRNA. VEGF is a high-affinity ligand for Fltl and Flk1. A
closely related member of the VEGF family is placental
growth factor (PlGF), which has 47% amino acid identity
with VEGF. PlGF also occurs in two alternatively spliced
forms which differ in the presence or absence of a basic
heparin binding domain of21 amino acids.
Various natural and synthetic mechanisms exist for modulating growth factor activity including those that regulate the
availability of agents that interact with growth factors in situ
and in vivo. Accordingly, additional compounds, compositions and methods for regulating growth factor-agent interactions are desirable.
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SUMMARY
Provided herein are compounds, compositions and methods for modulating angiogenesis in a target tissue. More
specifically, provided herein are compounds, compositions
and methods for modulating the bioavailability and activity of
growth factors such as VEGF and/or PlGF. Such compounds,
compositions and methods effectively modulate growth factor activity by regulating growth factor interactions with
growth factor inactivating agents. Such agents generally
regulate growth factor activity by sequestering the growth
factor in a complex that inhibits growth factor growth-promoting activities. Also provided are methods for identifying
compounds that modulate growth factor sequestration.
Accordingly, in various embodiments, methods of treating
or preventing a condition associated with decreased vascular-
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Conditions associated with decreased vascularity include
ocular disorders, preeclampsia, cerebrovascular disorders,
cardiovascular disorders, systemic hypertension, peripheral
vascular disease, vascular regeneration/recovery, and wound
healing disorders.
In one embodiment, the compound comprises a double
stranded nucleic acid molecule having one strand that is at
least 95% complementary to at least a portion of a nucleic
acid sequence encoding the agent. In one aspect, the nucleic
acid molecule comprises an interfering RNA molecule
selected from shRNA, siRNA and miRNA. The length of the
interfering RNA can be 10 to 80, 10 to 70, 10 to 60, 10 to 50,
10 to 40, or 10 to 30 nucleotides in length.
In another embodiment, the compound includes a purified
antibody or antigen-binding fragment that specifically binds
the agent.
In yet another embodiment, the expression of the agent is
regulated by an inducible excision system. In one aspect, the
inducible excision system is ere-lox or FLP/FRT excision
system. In general, excision is facilitated by the introduction
of exogenous CRE recombinase.
In some aspects, the compound is administered via a topical, intravitreal, transcleral, periocular, conjunctival, subtenon, intracameral, subretinal, subconjunctival, retrobulbar,
suprachoriodal, intravenous, oral or intracanalicular route. In
other aspects, the compound is included in a composition,
such as a pharmaceutically acceptable composition, which
facilitates administration of the compound to a subject.
In another embodiment, a short interfering nucleic acid
(siNA) molecule that promotes VEGF bioavailability by
down-regulating the expression of a polypeptide encoded by
the fms-like tyrosine kinase (Flt-1) gene. Exemplary
polypeptides include isoforms such as sflt-1 and mbflt-1.
In one aspect, the siNA molecule includes a sense region
and an antisense region. The antisense region includes a
sequence complementary to a sequence encoded by the fmslike tyrosine kinase (Flt-1) gene and the sense region includes
a sequence complementary to the antisense region. A siNA
molecule is assembled from two nucleic acid fragments--one
fragment includes the sense region and the second fragment
includes the antisense region of the siNA molecule. In some
aspects, the sense region and the antisense region are
covalently connected via a linker molecule, such as a polynucleotide linker or a non-nucleotide linker.
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In another aspect, the siNA molecule is RNA, such as
shRNA, siRNA and/or miRNA. In various other aspects, the
siNA molecule includes a sequence selected from: a) a
sequence comprising any one of SEQ ID NOs.: 1, 2, 3, 4, 5, 6,
or 7, and having a length of 21 to 50 nucleotides; b) a
sequence consisting of any one of SEQ ID NOs.: 1, 2, 3, 4, 5,
6, or 7; or c) a sequence comprising a region of at least 19
contiguous nucleotides having at least 90% sequence
complementarity to, or at least 90% sequence identity with,
anyoneofSEQIDN0:1, 2, 3, 4, 5, 6, or7, andhavingalength
of 21 to 50 nucleotides. In another aspect, a cell including a
siNA molecule of the invention is provided.
In another embodiment, a vector that includes a nucleic
acid sequence encoding at least one siNA molecule of the
invention in a marmer that allows expression of the nucleic
acid molecule is provided. In one aspect, the vector is
included in a cell, such as a mammalian cell.
In another embodiment, a siNA molecule of the invention
is linked to cell-penetrating peptide such as penetratin, transportan, pis!, TAT, pVEC, MTS, and MAP. In one aspect, the
cell penetrating peptide is linked to the 5' end of the siNA
molecule by a covalent bond.
In other embodiments, siRNA molecules provided herein
are included in a composition, such as a pharmaceutically
acceptable carrier.
In yet another embodiment, a method of identifYing a
compound that regulates the bioavailability or biological
activity ofVEGF in vivo or in situ, is provide. The method
includes a) contacting corneal tissue with a test compound
that regulates, or is believed to regulate: i) the expression of a
VEGF inactivating agent; or ii) the ability of the VEGF inactivating agent to bind to VEGF; b) measuring the bioavailability or biological activity of VEGF; and c) identifYing a
compound that regulates the bioavailability or biological
activity ofVEGF.
The details of one or more embodiments of the disclosure
are set forth in the accompanying drawings and the description below. Other features, objects, and advantages will be
apparent from the description and drawings, and from the
claims.

unique carboxyl terminus of sflt-1 specific antibody reveal
that mouse cornea (1) contains primarily sflt-1 (60 kDa) while
conjunctiva (2) contains primarily mbflt-1 (190 kDa).
FIG. 1, panel H depicts western blot analysis of two independent mouse cornea samples immunoprecipitated with
anti-VEGF-A antibody and immunoblotted with a biotinylated antibody against the amino (N)-terminus of flt-1 that
recognizes bothmbflt-1 and sflt-1 reveals that VEGF -A interacts with sflt-1 (60 kDa). Subsequent immunoblot with a
biotinylated anti-VEGF-A antibody confirms the pull-down
ofVEGF-A by the immunoprecipitating antibody.
FIG. 2, panel A depicts topical enzymatically active Cre
recombinase abolishes corneal avascularity in flt-1 1oxP!loxP
mice. NLS-Cre induces Cre expression (brown) in the cornea
within 1 hour of eye drop application as demonstrated by
immunolocalization in cell nuclei.
FIG. 2, panel B shows that NLS-~-galactosidase expression fails to induce Cre expression (brown) in cornea within 1
hour of eye drop application as demonstrated by immunolocalization in cell nuclei stained red.
FIG. 2, panel C depicts a reducing western blot of Cre
expression.
FIG. 2, panel D depicts Xgal staining of corneal flat mount
of ROSA26R lacZ reporter mouse confirms expression of
~-galactosidase (blue) 2 days after Cre expression.
FIG. 2, panel E depicts representative corneal flat mounts
showing CD31+ (green) LYVE-1- blood vessels in flt11oxP!loxP mouse corneas 14 days after treatment with NLSCre eye drops.
FIG. 2, panel F depicts representative corneal flat mounts
showing CD31+ (green) LYVE-1 blood vessels in flt11oxP!loxP mouse corneas 14 days after treatment with NLS~-galactosidase expression.
FIG. 2, panel G depicts the absence of corneal vascularization in wild-type mice after topical application ofNLS-Cre.
FIG. 2, panel H depicts the absence of corneal vascularization in wild-type mice after topical application of NLS-~
galactosidase.
FIG. 2, panel I depicts a western blot indicating that topical
application ofNLS-Cre leads to Cre expression in the mouse
cornea and is enhanced by the prior topical application of
proparacaine eye drops (+P) compared to no prior application
(-P).
FIG. 3, panel A is a bar graph indicating that sflt -1 mRNA
knockdown abolishes corneal avascularity. Real time RTPCR reveals reduced sflt-1 mRNA in wild-type mouse corneas 3 days after injection of pshRNA-sflt-1 but not pshRNAmbflt-1. * P<0.05, Bonferroni corrected Marm Whitney U
test. Error bars depict s.e.m.
FIG. 3, panel B is a bar graph depicting data generated from
an ELISA. The data indicates that sflt-1 protein is reduced in
wild-type mouse corneas 3 days after injection of pshRNAsflt-1 but not pshRNA-mbflt-1. * P<0.05, Bonferroni corrected Maun Whitney U test. Error bars depict s.e.m.
FIG. 3, panel C is a bar graph depicting data generated from
an ELISA. The data indicates that free VEGF-A protein is
increased in wild-type mouse corneas 3 days after injection of
pshRNA-sflt-1 but not pshRNA-mbflt-1. * P<0.05, Bonferroni corrected Mann Whitney U test. Error bars depict s.e.m.
FIG. 3, panel D provides an image of an eye expressing
pshRNA-sflt-1.
FIG. 3, panel E depicts a corneal flat mount showing
CD31 +(green) LYVE-1- blood vessels at 14 days after injection. pshRNA-sflt-1 expression induces CV in wild-type
mice. Scale bars are 500 f.tm.
FIG. 3, panel F depicts a corneal flat mount showing
CD31 +(green) LYVE-1- blood vessels at 14 days after injec-
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BRIEF DESCRIPTION OF DRAWINGS
This patent or application file contains at least one drawing
executed in color. Copies of this patent or patent application
publication with color drawing(s) will be provided by the
Office upon request and payment of the necessary fee.
FIG. 1, panel A is a photo of a human eye demonstrating
abrupt termination of blood vessels in the conjunctiva (CJ) at
its border with the cornea (C), the limbus (*).
FIG. 1, panel B depicts a non-reducing western blot of
mouse cornea revealing immunoreactive bands ofVEGF -A at
100-130 kDa corresponding to bound forms and negligible
immunoreactivity at 45-50 kDa corresponding to the free
form.
FIG.1, panel C depicts sflt-1 (lane 1) and VEGF-A (lane 3)
transcripts in mouse cornea identified by representative RTPCR. Lane 2 is water (template negative) control.
FIG. 1, panel D and panel E depict sflt-1 mRNA detected
by in situ hybridization in mouse corneal epithelium (epi) and
stroma (str). Antisense RNA probes show purple-brown reactivity. Sense RNA probes show negligible reactivity.
FIG. 1, panel F depicts immunolocalization (brown) of
sflt-1 protein in mouse cornea.
FIG. 1, panel G depicts reducing western blots using an
antibody against the amino (N)-terminus of flt-1 that recognizes both mbflt-1 and sflt-1 and an antibody against the
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tion. pshRNA-mbflt-1 expression fails to induce CV in wildtype mice. Scale bars are 500 f.tm.
FIG. 3, panel G is a graph depicting a decrease in sflt-1
(sVEGFRl) expression by a siRNA sequence that targets
sflt-1 (sVEGFRl).
FIG. 3, panel H depicts suppression of unique tail of sFLT
by siRNA targeting unique tail.
FIG. 3, panel I depicts suppression of mRNA of VEGF
binding domains (553 bp) of sFLT by siRNA targeting unique
tail, while 18sRNA (315 bp) is unaffected.
FIG. 3, panel J depicts western blot analysis of VEGF
expression (band visible at 25 kD) in mouse corneas using
immunoprecipitation by antibody to sFLT unique tail and
demonstrating that siRNA knock down of sflt-1 expression
frees VEGF from sflt-1 sequestration.
FIG. 4, panel A provides reducing western blots showing a
deficiency of sflt-1 in corneas of corn! and Pax6+1- mice
compared to background strain A/J and Pax6+1+ mice.
FIG. 4, panel B is a bar graph showing that sflt-1/Fc administration inhibits CV in corn! and Pax6+1- mice compared to
IgGl/Fc (by 87±2% in corn!; P=O.Ol; by 85±3% inPax6+1-;
P=0.03) and to control untreated mice (by 87±2% in corn!;
P=O.Ol; by 84±3% in Pax6+1-; P=0.03). Significance by Bonferroni corrected Mann Whitney U test. Error bars depict
s.e.m.
FIG. 4, panel C depicts flat mounts showing CD31 +(green)
LYVE-1-corneal blood vessels.
FIG. 4, panel D depicts immunostaining of a cornea and
revealing a deficiency of sflt-1 (brown) in cornea with aniridia-associated vascularization (top), revealed by vascular cell
adhesion molecule-! (VCAM-1) staining (red) compared to
the avascular cornea (lack ofVCAM -1 staining) of a different
cornea without aniridia (bottom).
FIG. 4, panel E depicts a marked deficiency of sflt-1 (reddish brown) staining in cornea of Antillean manatee.
FIG. 4, panel F depicts the presence of sflt-1 (reddish
brown) staining in cornea of a dugong.
FIG. 4, panel G depicts the presence of sflt-1 (reddish
brown) staining in cornea of an African elephant.
FIG. 4, panel H depicts the presence of sflt-1 (reddish
brown) staining in cornea of a beaked whale.
FIG. 4, panel I depicts reducing western blots using an
antibody against the amino (N) terminus offlt-1 reveal presence of sflt-1 (60 kDa) and absence ofmbflt-1 (190 kDa) in
corneas of bottlenose dolphin (1) and Asian elephant (2).
Scale bars are 200 flill·
FIG. 5 depicts a reducing western blot of Cre expression
showing that 1) AC injection of NLS-Cre leads to corneal
expression of Cre; 2) SC injection leads to expression in the
cornea, retina, and RPE/choroid; 3) VIT injection leads to
expression in lens, retina, and RPE/choroid; and 4) SR injection leads to expression in retina and RPE/choroid over 1 hr.
FIG. 6 depicts a reducing western blot of Cre expression
showing that 1) AC injection of NLS-Cre leads to corneal
expression of Cre; 2) SC injection leads to expression in the
cornea, retina, and RPE/choroid; 3) VIT injection leads to
expression in lens, retina, and RPE/choroid; and 4) SR injection leads to expression in retina and RPE/choroid over 3 hrs.
FIG. 7 depicts a reducing western blot of Cre expression
showing that 1) AC injection of NLS-Cre leads to corneal
expression of Cre; 2) SC injection leads to expression in the
cornea, retina, and RPE/choroid; 3) VIT injection leads to
expression in lens, retina, and RPE/choroid; and 4) SR injection leads to expression in retina and RPE/choroid over 8 hrs.
FIG. 8 depicts a reducing western blot of Cre expression
showing that 1) AC injection of NLS-Cre leads to corneal
expression of Cre; 2) SC injection leads to expression in the

cornea, retina, and RPE/choroid; 3) VIT injection leads to
expression in lens, retina, and RPE/choroid; and 4) SR injection leads to expression in retina and RPE/choroid over 24
hrs.
Like reference symbols in the various drawings indicate
like elements.
DETAILED DESCRIPTION
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Before describing the invention in detail, it is to be understood that this invention is not limited to particular compositions or biological systems, which can, of course, vary. It is
also to be understood that the terminology used herein is for
the purpose of describing particular embodiments only, and is
not intended to be limiting. As used in this specification and
the appended claims, the singular forms "a," "an," and "the"
include plural referents unless the content clearly dictates
otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which the
invention pertains. Although any methods and materials similar or equivalent to those described herein can be used in the
practice for testing of the invention( s), specific examples of
appropriate materials and methods are described herein.
As will be described in more detail below, the invention is
based, at least in part, on compounds, compositions and methods for regulating angiogenesis in a target tissue. More specifically, provided herein are compounds, compositions and
methods for modulating the bioavailability and activity of
VEGF or PlGF. Such compounds, compositions and methods
effectively modulate VEGF or PlGF activity by regulating
VEGF or PlGF interactions with VEGF or PlGF inactivating
agents. Such agents generally regulate VEGF or PlGF activity
by sequestering VEGF or PlGF in a complex that inhibits
VEGF or PlGF vascularization-promoting activities.
Accordingly, in various embodiments, methods of treating
or preventing a condition associated with decreased vascularity in a subject, are provided. The methods include administering to the subject a compound that regulates the bioavailability or biological activity ofVEGF or PlGF by modulating
the availability of a VEGF or PLGF inactivating agent. The
administering is sufficient to treat or prevent the condition in
the subject. An inactivating agent, as described herein, can
form a complex with VEGF or PlGF by binding to VEGF or
PlGF. A compound provided herein can modulate VEGF or
PlGF bioavailability or biological activity by preventing,
inhibiting or disrupting the formation of the complex. In one
aspect, this is accomplished by decreasing the amount of the
agent, such as by reducing or inhibiting the expression of the
agent. By "reduce or inhibit" is meant the ability to cause an
overall decrease of 20% or greater, more preferably of 40%,
50%, 60%, 70%, 80%, and 90% or greater change in the level
of the agent. By "expression" is meant the detection of a gene
or polypeptide by standard art known methods. For example,
polypeptide expression is often detected by western blotting,
DNA expression is often detected by Southern blotting or
polymerase chain reaction (PCR), and RNA expression is
often detected by northern blotting, PCR, or RNAse protection assays.
By "gene", or "target gene" or "target DNA", is meant a
nucleic acid that encodes an RNA, for example, nucleic acid
sequences including, but not limited to, structural genes
encoding a polypeptide. A gene or target gene can also encode
a functional RNA (fRNA) or non-coding RNA (ncRNA),
such as small temporal RNA (stRNA), micro RNA (miRNA),
small nuclear RNA (snRNA), short interfering RNA
(siRNA), small nucleolar RNA (snRNA), ribosomal RNA
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(rRNA), transfer RNA (tRNA) and precursor RNAs thereof.
Such non-coding RNAs can serve as target nucleic acid molecules for siNA mediated RNA interference in modulating
the activity of FRNA or ncRNA involved in functional or
regulatory cellular processes. Abberant fRNA or ncRNA
activity leading to disease can therefore be modulated by
siNA molecules of the invention. siNA molecules targeting
fRNA and ncRNA can also be used to manipulate or alter the
genotype or phenotype of a subject, organism or cell, by
intervening in cellular processes such as genetic imprinting,
transcription, translation, or nucleic acid processing (e.g.,
transamination, methylation etc.).
By "compound" is meant any small molecule chemical
compound, antibody, nucleic acid molecule, or polypeptide,
or fragments thereof. Compounds particularly useful for the
compositions and methods of the invention can alter, preferably increase, the bioavailability or biological activity of
VEGF or PlGF by at least 10%, 20%, 30%, 40%, 50%, 60%,
70%, 80%, 90% or more. Accordingly, the compounds, compositions and methods provided herein can be used to treat
conditions associated with decreased vascularity. For
example, tissue that requires vascularization, neovascularization and/or revascularization of in a subject can be treated by
a compound, composition or method provided herein. Such
conditions are described in more detail below and include
ocular disorders, preeclampsia, cerebrovascular disorders,
cardiovascular disorders, and wound healing disorders, or
any proliferative, inflammatory or neurologic disorder that
can be successfully treated or prevented by increasing the
bioavailability or biological activity of a growth factor.
Accordingly, in one embodiment, compounds provided
herein include nucleobase oligomers that regulate the expression of a target nucleic acid sequence encoding an inactivating agent. By "nucleobase oligomer" is meant an oligomer,
regardless of length, that is complementary to the coding
strand or mRNA of any nucleic acid sequence encoding an
inactivating agent. A nucleobase oligomer generally includes
a chain of at least eight, twelve, or at least sixteen nucleobases, joined together by linkage groups. Included in this
definition are natural and non-natural oligonucleotides, both
modified and unmodified, as well as oligonucleotide mimetics such as Protein Nucleic Acids, locked nucleic acids, and
arabinonucleic acids. Numerous nucleobases and linkage
groups may be employed in the nucleobase oligomers of the
invention, including those described in U.S. patent Publication Nos. 20030114412 (see for example paragraphs 27-45 of
the publication) and 20030114407 (see for example paragraphs 35-52 of the publication), incorporated herein by reference. The nucleobase oligomer can also be targeted to the
translational start and stop sites.
The term "nucleobase oligomer" includes short interfering
nucleic acid (siNA) molecules such as dsRNA, siRNA,
shRNA, miRNA or mimetics thereof that inhibits the expression of a target gene (see below). An inhibitory nucleobase
oligomer typically reduces the amount of a target mRNA, or
protein encoded by such mRNA, by at least 5%, more desirable by at least 10%, 25%, 50%, or even by 7 5%, 85%, or 90%
relative to an untreated control. Methods for measuring both
mRNA and protein levels are well-known in the art; exemplary methods are described herein. The nucleobase oligomer
(or a portion thereof) may contain a modified backbone.
Phosphorothioate, phosphorodithioate, and other modified
backbones are known in the art. The nucleobase oligomer
may also contain one or more non-natural linkages.
Specific examples of some modified nucleic acids or
nucleobases envisioned for this invention may contain phosphorothioates, phosphotriesters, methyl phosphonates, short

chain alkyl or cycloalkyl intersugar linkages or short chain
heteroatomic or heterocyclic intersugar linkages. In other
embodiments, such as the protein-nucleic acid (PNA) backbone, the phosphodiester backbone of the oligonucleotide
may be replaced with a polyamide backbone, the bases being
bound directly or indirectly to the aza nitrogen atoms of the
polyamide backbone (Nielsen et a!., Science 254:1497
(1991)). Other preferred oligonucleotides may contain alkyl
and halogen-substituted sugar moieties. Oligonucleotides
may also have sugar mimetics such as cyclobutyls in place of
the pentofuranosyl group. Other embodiments may include at
least one modified base form. Some specific examples of such
modified bases include 2-(amino)adenine, 2-(methylamino)
adenine, 2-(imidazolylalkyl)adenine, 2-(aminoalklyamino)
adenine, or other heterosubstituted alkyladenines. Each of the
above is referred to as a "modification" herein.
As previously noted, a nucleobase oligomer includes small
nucleic acid molecules useful for RNA interference (RNAi),
such as short interfering nucleic acid (siNA), short interfering
RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA
(miRNA), and short hairpin RNA (shRNA) molecules
capable of mediating or that mediate RNA interference
(RNAi) against the expression ofVEGF or PlGF inactivating
agents, such as polypeptide encoded by the fms-like tyrosine
kinase (Flt-1) gene. Such small nucleic acid molecules are
useful, for example, in providing compositions for treatment
of traits, diseases and conditions that can respond to modulation of VEGF or PlGF activity in a subject or organism.
Such proliferative diseases and conditions include ocular diseases and conditions, dermatological diseases and conditions, and any other disease, condition, trait or indication that
can respond to the level ofVEGF activity in a cell or tissue.
Accordingly, nucleobase oligomers provided herein
include short interfering nucleic acid (siNA) molecules. The
term "short interfering nucleic acid", "siNA", "short interfering RNA", "siRNA", "short interfering nucleic acid molecule", "short interfering oligonucleotide molecule", or
"chemically-modified short interfering nucleic acid molecule" as used herein refers to any nucleic acid molecule
capable of inhibiting or down regulating expression of an
inactivating agent by mediating RNA interference "RNAi" or
gene silencing in a sequence-specific marmer. For example
the siNA can be a double-stranded nucleic acid molecule
comprising self-complementary sense and antisense regions,
wherein the antisense region comprises nucleotide sequence
that is complementary to nucleotide sequence in a target
nucleic acid molecule or a portion thereof and the sense
region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof. The siNA can
be assembled from two separate oligonucleotides, where one
strand is the sense strand and the other is the antisense strand,
wherein the antisense and sense strands are self-complementary (i.e., each strand comprises nucleotide sequence that is
complementary to nucleotide sequence in the other strand;
such as where the antisense strand and sense strand form a
duplex or double stranded structure, for example wherein the
double stranded region is about 15 to about 30, e.g., about 15,
16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,29 or 30 base
pairs; the antisense strand comprises nucleotide sequence that
is complementary to nucleotide sequence in a target nucleic
acid molecule or a portion thereof and the sense strand comprises nucleotide sequence corresponding to the target
nucleic acid sequence or a portion thereof (e.g., about 15 to
about 25 or more nucleotides of the siNA molecule are
complementary to the target nucleic acid or a portion thereof).
Alternatively, the siNA is assembled from a single oligonucleotide, where the self-complementary sense and anti-
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sense regions of the siNA are linked by means of a nucleic
acid based or non-nucleic acid-based linker(s ). The siNA can
be a polynucleotide with a duplex, asymmetric duplex, hairpin or asymmetric hairpin secondary structure, having selfcomplementary sense and antisense regions, wherein the antisense region comprises nucleotide sequence that is
complementary to nucleotide sequence in a separate target
nucleic acid molecule or a portion thereof and the sense
region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof. The siNA can
be a circular single-stranded polynucleotide having two or
more loop structures and a stem comprising self-complementary sense and antisense regions, wherein the antisense region
comprises nucleotide sequence that is complementary to
nucleotide sequence in a target nucleic acid molecule or a
portion thereof and the sense region having nucleotide
sequence corresponding to the target nucleic acid sequence or
a portion thereof, and wherein the circular polynucleotide can
be processed either in vivo or in vitro to generate an active
siNA molecule capable of mediating RNAi. The siNA can
also comprise a single stranded polynucleotide having nucleotide sequence complementary to nucleotide sequence in a
target nucleic acid molecule or a portion thereof (for example,
where such siNA molecule does not require the presence
within the siNA molecule of nucleotide sequence corresponding to the target nucleic acid sequence or a portion
thereof), wherein the single stranded polynucleotide can further comprise a terminal phosphate group, such as a 5'-phosphate, or 5',3'-diphosphate.
In some embodiments, the siNA molecule of the invention
comprises separate sense and antisense sequences or regions,
wherein the sense and antisense regions are covalently linked
by nucleotide or non-nucleotide linkers molecules as is
known in the art, or are alternately non-covalently linked by
ionic interactions, hydrogen bonding, van der waals interactions, hydrophobic interactions, and/or stacking interactions.
In certain embodiments, the siNA molecules of the invention
comprise nucleotide sequence that is complementary to
nucleotide sequence of a target gene. In another embodiment,
the siNA molecule of the invention interacts with nucleotide
sequence of a target gene in a manner that causes inhibition of
expression of the target gene. As used herein, siNA molecules
need not be limited to those molecules containing only RNA,
but further encompasses chemically-modified nucleotides
and non-nucleotides. In certain embodiments, the short interfering nucleic acid molecules of the invention lack 2'-hydroxy
(2'-0H) containing nucleotides. Applicant describes in certain embodiments short interfering nucleic acids that do not
require the presence of nucleotides having a 2'-hydroxy group
for mediating RNAi and as such, short interfering nucleic acid
molecules of the invention optionally do not include any
ribonucleotides (e.g., nucleotides having a 2'-0H group).
Such siNA molecules that do not require the presence of
ribonucleotides within the siNA molecule to support RNAi
can however have an attached linker or linkers or other
attached or associated groups, moieties, or chains containing
one or more nucleotides with 2'-0H groups. Optionally, siNA
molecules can comprise ribonucleotides at about 5, 10, 20,
30, 40, or 50% of the nucleotide positions. The modified short
interfering nucleic acid molecules of the invention can also be
referred to as short interfering modified oligonucleotides
"siMON." As used herein, the term siNA is meant to be
equivalent to other terms used to describe nucleic acid molecules that are capable of mediating sequence specific RNAi,
for example short interfering RNA (siRNA), double-stranded
RNA (dsRNA), micro-RNA (miRNA), short hairpin RNA
(shRNA), short interfering oligonucleotide, short interfering

nucleic acid, short interfering modified oligonucleotide,
chemically-modified siRNA, post-transcriptional gene
silencing RNA (ptgsRNA), and others. Short hairpin interfering RNA (shRNA) is a single molecule (e.g., a single oligonucleotide chain) that comprises both the sense and antisense
strands of an interfering RNA in a stem-loop or hairpin structure (e.g., a shRNA). For example, shRNAs can be expressed
from DNA vectors in which the DNA oligonucleotides
encoding a sense interfering RNA strand are linked to the
DNA oligonucleotides encoding the reverse complementary
antisense interfering RNA strand by a short spacer. If needed
for the chosen expression vector, 3' terminal T's and nucleotides forming restriction sites may be added. The resulting
RNA transcript folds back onto itself to form a stem-loop
structure.
Each sequence of a siNA molecule of the invention is
independently about 15 to about 30 nucleotides in length, in
specific embodiments about 15, 16, 17, 18, 19, 20, 21, 22, 23,
24, 25, 26, 27, 28, 29, or 30 nucleotides in length. In another
embodiment, the siNA duplexes of the invention independently comprise about 15 to about 30 base pairs (e.g., about
15, 16, 17, 18, 19,20,21,22,23,24,25,26,27,28,29,or30).
One or more strands of the siNA molecule of the invention
independently comprises about 15 to about 30 nucleotides
(e.g., about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,
29, or 30) that are complementary to a target nucleic acid
molecule. siNA molecules of the invention comprising hairpin or circular structures are about 35 to about 55 (e.g., about
35, 40, 45, 50 or 55) nucleotides in length, or about 38 to about
44 (e.g., about 38, 39, 40, 41, 42, 43, or 44) nucleotides in
length and comprising about 15 to about 25 (e.g., about 15,
16, 17, 18, 19, 20, 21, 22, 23, 24, or 25) base pairs.
siNA molecules provided herein include those that having
a sequence of any one of SEQ ID NOs.: 1, 2, 3, 4, 5, 6, or 7.
Such molecules include those that consist of any one of SEQ
ID NOs.:1, 2, 3, 4, 5, 6, or 7. In addition, siNA molecules
provided herein include those having a region of at least 19
contiguous nucleotides having at least 90% sequence
complementarity to, or at least 90% sequence identity with,
any one of SEQ ID N0:1, 2, 3, 4, 5, 6, or 7. "Sequence
identity" herein means the extent to which two nucleotide
sequences are invariant. "Sequence alignment" means the
process oflining up two or more sequences to achieve maximallevels of identity for the purpose of assessing the degree
of similarity. Numerous methods for aligning sequences and
assessing similarity/identity are known in the art such as, for
example, the Cluster Method, wherein similarity is based on
the MEGALIGN algorithm, as well as BLASTN, BLASTP,
and PASTA (Lipman and Pearson, 1985; Pearson and Lipman, 1988). When using all of these programs, the preferred
settings are those that results in the highest sequence similarity.
By "RNA interference" or "RNAi" is meant a biological
process of inhibiting or down regulating gene expression in a
cell as is generally known in the art and which is mediated by
short interfering nucleic acid molecules, see for example
Zamore and Haley, Science, 309: 1519; Vaughn and Marti enssen, Science, 309: 1525; and Kreutzer et a!., International
PCT Publication No. WO 00/44895; Zernicka-Goetz eta!.,
International PCT Publication No. WO 01/36646; Fire, International PCT Publication No. WO 99/32619; Plaetinck eta!.,
International PCT Publication No. WO 00/01846; Mello and
Fire, International PCT Publication No. WO 01/29058; Deschamps-Depaillette, International PCT Publication No. WO
99/07409; and Li et a!., International PCT Publication No.
WO 00/44914). In addition, as used herein, the term RNAi is
meant to be equivalent to other terms used to describe
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sequence specific RNA interference, such as post transcriptional gene silencing, translational inhibition, transcriptional
inhibition, or epigenetics. For example, siNA molecules of
the invention can be used to epigenetically silence genes at
both the post-transcriptional level or the pre-transcriptional
level. In a non-limiting example, epigenetic modulation of
gene expression by siNA molecules of the invention can
result from siNA mediated modification of chromatin structure or methylation patterns to alter gene expression. In
another non-limiting example, modulation of gene expression by siNA molecules of the invention can result from siNA
mediated cleavage of RNA (either coding or non-coding
RNA) via RISC, or alternately, translational inhibition as is
known in the art. In another embodiment, modulation of gene
expression by siNA molecules of the invention can result
from transcriptional inhibition (see for example Janowski et
a!., 2005, Nature Chemical Biology, 1:216).
RNA interference (RNAi) is a process by which doublestranded RNA (dsRNA) is used to silence gene expression.
While not wanting to be bound by theory, RNAi begins with
the cleavage of longer dsRNAs into small interfering RNAs
(siRNAs) by an RNaseiii-like enzyme, dicer. SiRNAs are
dsRNAs that are usually about 19 to 28 nucleotides, or 20 to
25 nucleotides, or 21 to 22 nucleotides in length and often
contain 2-nucleotide 3' overhangs, and 5' phosphate and 3'
hydroxyl termini. One strand of the siRNA is incorporated
into a ribonucleoprotein complex known as the RNA-induced
silencing complex (RISC). RISC uses this siRNA strand to
identify mRNA molecules that are at least partially complementary to the incorporated siRNA strand, and then cleaves
these target mRNAs or inhibits their translation. Therefore,
the siRNA strand that is incorporated into RISC is known as
the guide strand or the antisense strand. The other siRNA
strand, known as the passenger strand or the sense strand, is
eliminated from the siRNA and is at least partially homologous to the target mRNA. Those of skill in the art will recognize that, in principle, either strand of an siRNA can be
incorporated into RISC and function as a guide strand. However, siRNA design (e.g., decreased siRNA duplex stability at
the 5' end of the antisense strand) can favor incorporation of
the antisense strand into RISC.
Interfering RNA of embodiments of the invention appear to
act in a catalytic manner for cleavage of target mRNA, i.e.,
interfering RNA is able to effect inhibition of inactivating
agent expression in substoichiometric amounts. As compared
to antisense therapies, significantly less interfering RNA is
required to provide a therapeutic effect under such cleavage
conditions. siNA molecules of the invention include duplex
forming oligonucleotides "DFOs", (see for example Vaish et
a!., U.S. Ser. No. 10/727,780 filed Dec. 3, 2003 and International PCT Application No. US04/16390, filed May 24,
2004).
In some embodiments, an siNA molecule provided herein
can be functionally associated with a cell-penetrating peptide." As used herein, a "cell-penetrating peptide" is a peptide
that comprises a short (about 12-30 residues) amino acid
sequence or functional motif that confers the energy-independent (i.e., non-endocytotic) translocation properties associated with transport of the membrane-permeable complex
across the plasma and/or nuclear membranes of a cell. The
cell-penetrating peptide used in the membrane-permeable
complex of the present invention preferably comprises at
least one non-functional cysteine residue, which is either free
or derivatized to form a disulfide link with a double-stranded
ribonucleic acid that has been modified for such linkage.
Representative amino acid motifs conferring such properties
are listed in U.S. Pat. No. 6,348,185, the contents of which are

expressly incorporated herein by reference. The cell-penetrating pep tides of the present invention preferably include,
but are not limited to, penetratin, transportan, pis!, TAT(4860), pVEC, MTS, and MAP.
Penetratin is a 16-amino-acid polypeptide derived from the
third alpha-helix of the homeodomain of Drosophila antennapedia. Its structure and function have been well studied and
characterized: Derossi et a!., Trends Cell Bioi., 8:84-87,
1998; Dunican eta!., Biopolymers, 60:45-60, 2001; Hallbrink et a!., Biochim. Biophys. Acta, 1515:101-09, 2001;
Bolton eta!., Eur. J. Neurosci., 12:2847-55, 2000; Kilk eta!.,
Bioconjug. Chern., 12:911-16, 2001; Bellet-Amalric eta!.,
Biochim. Biophys.Acta, 1467:131-43, 2000; Fischer eta!., J.
Pept. Res., 55: 163-72, 2000; Thoren et a!., FEBS Lett.,
482:265-68, 2000.
As previously noted, a compound provided herein modulates the ability of an inactivating agent to form a complex
with VEGF or PIGF by binding to VEGF or PIGF. An "inactivating agent," as used herein includes any polypeptide
encoded by the fms-like tyrosine kinase (Flt-1) gene. Exemplary polypeptides include isoforms such as sflt-1 and mbflt-
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In another embodiment, a compound provided herein
includes antibodies that prevent, inhibit or disrupt the formation of a growth factor-inactivating agent complex by specifically binding to the inactivating agent. Such neutralizing
antibodies include polyclonal as well as monoclonal antibodies. The production and identification of antibodies that bind
to a target molecule is well known in the art. By "specifically
binds" is meant a compound or antibody which recognizes
and binds the inactivating agent but that does not substantially
recognize and bind other molecules in a sample, for example,
a biological sample, which naturally includes a polypeptide
of the invention.
Also included are humanized antibodies. By "humanized
antibody" is meant an immunoglobulin amino acid sequence
variant or fragment thereof that is capable of binding to a
predetermined antigen. Ordinarily, the antibody will contain
both the light chain as well as at least the variable domain of
a heavy chain. The antibody also may include the CHI, hinge,
CH2, CH3, or CH4 regions of the heavy chain. The humanized antibody comprises a framework region (FR) having
substantially the amino acid sequence of a human immunoglobulin and a complementarity determining region (CDR)
having substantially the amino acid sequence of a non-human
immunoglobulin (the "import" sequences).
Generally, a humanized antibody has one or more amino
acid residues introduced into it from a source that is nonhuman. In general, the humanized antibody will comprise
substantially all of at least one, and typically two, variable
domains (Fab, Fab', F(ab').sub.2, Fabc, Fv) in which all or
substantially all of the CDR regions correspond to those of a
non-human immunoglobulin and all or substantially all of the
FR regions are those of a human immunoglobulin consensus
sequence. The humanized antibody optimally will comprise
at least a portion of an immunoglobulin constant region (Fe),
typically that of a human immunoglobulin. By "complementarily determining region (CDR)" is meant the three hypervariable sequences in the variable regions within each of the
immunoglobulin light and heavy chains. By "framework
region (FR)" is meant the sequences of amino acids located
on either side of the three hypervariable sequences (CDR) of
the immunoglobulin light and heavy chains.
The FR and CDR regions of the humanized antibody need
not correspond precisely to the parental sequences, e.g., the
import CDR or the consensus FR may be mutagenized by
substitution, insertion or deletion of at least one residue so
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that the CDR or FR residue at that site does not correspond to
either the consensus or the import antibody. Such mutations,
however, will not be extensive. Usually, at least 75%, preferably 90%, and most preferably at least 95% of the humanized
antibody residues will correspond to those of the parental FR
and CDR sequences.
In yet another embodiment, a compound of the invention
includes compounds that facilitate the ablation of a genetic
sequence encoding an inactivating agent. Such compounds
include Cre recombinase (e.g., NLS-Cre) which can be used
in methods of achieving on-demand ere-lox recombination
for gene deletion. The data provided herein indicate that
NLS-Cre can be injected into various different compartments
of the eye to achieve spatial targeting of any gene. Further, the
present studies demonstrate that application of topical eye
drops ofNLS-Cre lead to ere-expression and recombination
and gene deletion of "floxed" genes in the cornea. Accordingly, methods of conditionally reducing the expression of a
coding sequence in a target cell are provided. The term "conditionally reduced expression" refers to the flexibility inherent in the methods/vectors of this invention, which enable
regulation of reducing expression of a coding sequence in a
target cell. In one embodiment, reducing expression via the
vectors/methods of this invention is controlled overtime, or in
a cell or tissue-specific manner.
The ere recombinase is derived from a P1 bacteriophage
(Abremski andHoess, J. Bioi. Chern. 259:1509, 1984) which
acts on a specific 34 base pair DNA sequence known as
"loxP" (locus of crossover), which is, in turn, comprised of
two 13 base pair inverted repeats (serving as the recombinase
binding sites) flanking an 8 base pair core sequence (Current
Opinion in Biotechnology 5:521, 1994). Cre catalyzes the
rearrangement of DNA sequences that contain loxP sites.
Recombination between two loxP sites (catalyzed by the ere
protein) causes, in certain cases, the loss of sequences flanked
by these sites (for a review seeN. Kilby eta!, Trends Genet.,
9:413, 1993). Compounds, compositions and methods provided herein encompass the introduction of Cre recombinase
in to a cell or tissue in order to conditionally regulate the
expression of a VEGF or FIGF inactivating agent by genomic
deletion. For example, sflt-1 expression was suppressed by
conditional Cre-lox mediated gene ablation by topical application ofNLS-Cre and by corneal injection of plasmid encoding Cre recombinase (pCre) in flt-1 1oxP!loxP mouse eyes;
P<O.OOl) within 2 days. Cre expression was accompanied by
significantly reduced sflt -1 and increased free VEGF-A. N either plasmid induced CV in wild-type mice. To avoid injection trauma, a cell permeable enzymatically active Cre containing a nuclear localization sequence (NLS-Cre) was
delivered to the cornea by topical eye drops (FIG. 2, panels
A-D). NLS-Cre, but not NLS-~-galactosidase, induced CV in
flt-1 1oxP!loxP mouse eyes (P<O.OOl) within 2 days (FIG. 2,
panels E and F). Neither NLS-enzyme induced CV in wildtype mice (FIG. 2, panels G and H).
As noted throughout the present specification, compounds
that regulate the bioavailability or biological activity of
VEGF or PIGF by modulating the availability of a VEGF or
PLGF inactivating agent, are provided. By "modulate" or
"regulate" is meant that the expression of the gene, or level of
a RNA molecule or equivalent RNA molecules encoding one
or more proteins or protein subunits, or activity of one or more
proteins or protein subunits is up regulated or down regulated,
such that expression, level, or activity is greater than or less
than that observed in the absence of the modulator or regulator, i.e., a compound provided herein. For example, the term
"modulate" or "regulate" can mean "inhibit," "prevent,"

"facilitate," or "promote," but the use of the word "modulate"
or "regulate" is not limited to these definitions.
By "inhibit", "down-regulate", or "reduce", it is meant that
the expression of gene encoding an inactivating agent, or level
of RNA molecules or equivalent RNA molecules encoding
one or more proteins or protein subunits associated with an
inactivating agent, or activity of one or more proteins or
protein subunits of an agent, is reduced below that observed in
the absence of the compounds (e.g., siNA, antibodies, or gene
ablation compounds) of the invention. In one embodiment,
inhibition, down regulation, or reduction of gene expression
is associated with post transcriptional silencing, such as
RNAi mediated cleavage of a target nucleic acid molecule
(e.g. RNA) or inhibition of translation. In one embodiment,
inhibition, down regulation, or reduction of gene expression
is associated with pretranscriptional silencing, such as by
gene ablation.
The compounds, compositions and methods decribed
herein allow for the upregulation of growth factor protein
bioavialibility or biological activity by inhibiting or downregulating the presence of a growth factor inactivating agent.
By "up-regulate", or "promote", it is meant that the activity of
one or more proteins or protein subunits, is increased above
that observed in the absence of the nucleic acid molecules
(e.g., siNA) of the invention. In one embodiment, up-regulation of growth factor bioavailability includes using a compound, such as an siNA molecule, to down regulate the availability of an inactivating reagent, such as sflt-1. The down
regulation of gene expression can, for example, be induced by
a coding RNA or its encoded protein, such as through negative feedback or antagonistic effects. The down regulation of
gene expression can, for example, be induced by a noncoding RNA having regulatory control over a gene of interest,
for example by silencing expression of the gene via translational inhibition, chromatin structure, methylation, RISC
mediated RNA cleavage, or translational inhibition. As such,
inhibition or down regulation of targets that down regulate,
suppress, or inactivate a growth factor of interest can be used
to up-regulate or promote the bioavailability of the growth
factor of interest toward therapeutic use.
Throughout the present specification, compounds, compositions and methods are described that are useful for modulating angiogenesis an/or vasculogenesis by promoting the
activity of growth factors associated with such processes. The
compounds, compositions and methods generally target
growth factor-inactivating agents such that the bioavailability
or biological activity of a growth factor is increased.
Angiogenesis is a process of new blood vessel development from pre-existing vasculature. It plays an essential role
in embryonic development, normal growth of tissues, wound
healing, the female reproductive cycle (i.e., ovulation, menstruation and placental development), as well as a major role
in many diseases. One of the most important growth and
survival factors for endothelium is vascular endothelial
growth factor (VEGF). VEGF induces angiogenesis and
endothelial-cell proliferation and plays an important role in
regulating vasculogenesis. VEGF is a heparin-binding glycoprotein that is secreted as a homodimer of 45 kDa. Most types
of cells, but usually not endothelial cells themselves, secrete
VEGF. Since the initially discovered VEGF, VEGF-A,
increases vascular permeability, it was known as vascular
permeability factor. In addition, VEGF causes vasodilatation,
partly through stimulation of nitric oxide synthase in endothelial cells. VEGF can also stimulate cell migration and
inhibit apoptosis (see "R&D Systems, Cytokine Mini
Reviews, Vascular Endothelial Growth Factor (VEGF),"
Copyright 2002 R&D Systems).
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There are several splice variants ofVEGF-A. The major
ones include: 121, 165, 189 and 206 amino acids (aa), each
one comprising a specific exon addition. VEGF165 is the
most predominant protein, but transcripts ofVEGF 121 may
be more abundant. VEGF206 is rarely expressed and has been
detected only in fetal liver. Recently, other splice variants of
145 and 183 aa have also been described. The 165, 189 and
206 aa splice variants have heparin-binding domains, which
help anchor them in extracellular matrix and are involved in
binding to heparin sulfate and presentation to VEGF receptors. Such presentation is a key factor for VEGF potency (i.e.,
the heparin-binding forms are more active). Several other
members of the VEGF family have been cloned including
VEGF-B, -C, and -D. Placenta growth factor (PIGF) is also
closely related to VEGF-A. VEGF-A, -B, -C, -D, and PIGF
are all distantly related to platelet-derived growth factors-A
and -B. Less is known about the function and regulation of
VEGF -B, -C, and -D, but they do not seem to be regulated by
the major pathways that regulate VEGF -A.
VEGF-A transcription is potentiated in response to
hypoxia and by activated oncogenes. The transcription factors, hypoxia inducible factor-1a (hif-1a) and -2a, are
degraded by proteosomes in normoxia and stabilized in
hypoxia. This pathway is dependent on the Von RippelLindau gene product. Hif-1a and hif-2 a heterodimerize with
the aryl hydrocarbon nuclear translocator in the nucleus and
bind the VEGF promoter/enhancer. This is a key pathway
expressed in most types of cells. Hypoxia inducibility, in
particular, characterizes VEGF-A versus other members of
the VEGF family and other angiogenic factors.
There are three receptors in the VEGF receptor family.
They have the common properties of multiple IgG-like extracellular domains and tyrosine kinase activity. The enzyme
domains ofVEGF receptor 1 (VEGFR1, also known as Flt-1 ),
VEGFR2 (also known as KDR or Flk-1), and VEGFR3 (also
known as Flt-4) are divided by an inserted sequence. Endothelial cells also express additional VEGF receptors, Neuropilin-1 and Neuropilin-2. VEGF-A binds to VEGFR1 and
VEGFR2 and to Neuropilin-1 and Neuropilin-2. PIGF and
VEGF-B bind VEGFR1 and Neuropilin-1. VEGF-C and -D
bind VEGFR3 and VEGFR2.
Accordingly, by "vascular endothelial growth factor
(VEGF)" is meant a mmalian growth factor that is
homologous to the growth factor defined in U.S. Pat. Nos.
5,332,671; 5,240,848; 5,194,596; and Charnock-Janes eta!.
(Bioi. Reproduction, 48: 1120-1128, 1993), and has VEGF
biological activity. VEGF exists as a glycosylated homodimer
and includes at least four different alternatively spliced isoforms. The biological activity of native VEGF includes the
promotion of selective growth of vascular endothelial cells or
umbilical vein endothelial cells and induction of angiogenesis. As used herein, VEGF includes any VEGF family memberorisoform (e.g., VEGF-A, VEGF-B, VEGF-C, VEGF-D,
VEGF-E, VEGF189, VEGF165, orVEGF 121). Preferably,
VEGF is the VEGF121 orVEGF165 isoform (Tischer eta!.,
J. Bioi. Chern. 266, 11947-11954, 1991; Neufed eta!. Cancer
Metastasis 15:153-158, 1996), which is described in U.S. Pat.
Nos. 6,447,768; 5,219,739; and 5,194,596, hereby incorporated by reference. Also included are mutant forms ofVEGF
such as the KDR-selective VEGF and Fit-selective VEGF
described in Gille et a!. (J. Bioi. Chern. 276:3222-3230,
2001 ). As used herein VEGF also includes any modified
forms of VEGF such as those described in LeCouter et a!.
(Science 299:890-893, 2003 ). Although human VEGF is preferred, the invention is not limited to human forms and can
include other animal forms ofVEGF (e.g. mouse, rat, dog, or
chicken). The term VEGF also refers to nucleic acid

sequences encoding any vascular endothelial growth factor
protein, peptide, or polypeptide having vascular endothelial
growth factor activity.
By "VEGF-B" is meant, protein, peptide, or polypeptide
receptor or a derivative thereof, such as encoded by Genbank
Accession No. NM 003377, having vascular endothelial
growth factor type B activity. The term VEGF -B also refers to
nucleic acid sequences encoding any VEGF -B protein, peptide, or polypeptide having VEGF -B activity.
By "VEGF -C" is meant, protein, peptide, or polypeptide
receptor or a derivative thereof, such as encoded by Genbank
Accession No. NM 005429, having vascular endothelial
growth factor type C activity. The term VEGF -C also refers to
nucleic acid sequences encoding any VEGF -C protein, peptide, or polypeptide having VEGF -C activity.
By "VEGF-D" is meant, protein, peptide, or polypeptide
receptor or a derivative thereof, such as encoded by Genbank
Accession No. NM 004469, having vascular endothelial
growth factor typeD activity. The term VEGF -D also refers to
nucleic acid sequences encoding any VEGF-D protein, peptide, or polypeptide having VEGF -D activity.
By "VEGFR" as used herein is meant, any vascular endothelial growth factor receptor protein, peptide, or polypeptide
(e.g., VEGFR1, VEGFR2, orVEGFR3, including both membrane bound and/or soluble forms thereof) having vascular
endothelial growth factor receptor activity. The term VEGFR
also refers to nucleic acid sequences encoding any vascular
endothelial growth factor receptor protein, peptide, or
polypeptide having vascular endothelial growth factor receptor activity.
By "VEGFR1," "sVEGFR1," or"sflt-1" is meant, protein,
peptide, or polypeptide receptor or a derivative thereof, such
as encoded by GenbankAccession No. NM 002019 or GenBank accession number U01134, having vascular endothelial
growth factor receptor type 1 (fit) activity, for example, having the ability to bind a vascular endothelial growth factor.
The term VEGF 1 also refers to nucleic acid sequences encoding any VEGFR1 protein, peptide, or polypeptide having
VEGFR1 activity. The biological activity of an sF!t-1
polypeptide may be assayed using any standard method, for
example, by assaying sF!t-1 binding to VEGF. sF!t-1lacks the
transmembrane domain and the cytoplasmic tyrosine kinase
domain of the Flt-1 receptor. sF!t-1 can bind to VEGF and
PIGF with high affinity, but it caunot induce proliferation or
angiogenesis and is therefore functionally different from the
Flt-1 and KDR receptors. sF!t-1 was initially purified from
human umbilical endothelial cells and later shown to be produced by trophoblast cells in vivo. As used herein, sF!t-1
includes any sF!t-1 family member or isoform. sF!t-1 can also
mean degradation products or fragments that result from
enzymatic cleavage of the Flt-1 receptor and that maintain
sF!t-1 biological activity. In one example, specific metalloproteinases released from the placenta may cleave the extracellular domain of Flt-1 receptor to release theN-terminal
portion ofF!t-1 into circulation.
A soluble form of Flt-1 (sflt-1) can be detected in peripheral blood and is a high affinity ligand for VEGF. Soluble
Flt-1 can be used to antagonize VEGF function. VEGFR1 and
VEGFR2 are upregulated in tumor and proliferating endothelium, partly by hypoxia and also in response to VEGF-A
itself. VEGFR1 and VEGFR2 can interact with multiple
downstream signaling pathways via proteins such as PLC-g,
Ras, She, Nck, PKC and PI3-kinase. VEGFR1 is of higher
affinity than VEGFR2 and mediates motility and vascular
permeability. VEGFR2 is necessary for proliferation.
By "VEGFR2" is meant, protein, peptide, or polypeptide
receptor or a derivative thereof, such as encoded by Genbank
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By "ocular disease" as used herein is meant, any disease,
Accession No. NM 002253, having vascular endothelial
growth factor receptor type 2 (kdr) activity, for example,
condition, trait, genotype or phenotype of the eye and related
having the ability to bind a vascular endothelial growth factor.
structures as is known in the art, such as Cystoid Macular
The term VEGF2 also refers to nucleic acid sequences encodEdema, Asteroid Hyalosis, Pathological Myopia and Posteing any VEGFR2 protein, peptide, or polypeptide having
rior Staphyloma, Toxocariasis (Ocular Larva Migrans ), Retinal Vein Occlusion, Posterior Vitreous Detachment, TracVEGFR2 activity.
By "VEGFR3" is meant, protein, peptide, or polypeptide
tional Retinal Tears, Epiretinal Membrane, Diabetic
Retinopathy, Lattice Degeneration, Retinal Vein Occlusion,
receptor or a derivative thereof, such as encoded by Genbank
Retinal Artery Occlusion, Macular Degeneration (e.g., age
Accession No. NM 002020 having vascular endothelial
growth factor receptor type 3 (kdr) activity, for example, 1o related macular degeneration such as wet AMD or dry AMD ),
having the ability to bind a vascular endothelial growth factor.
Toxoplasmosis, Choroidal Melanoma, Acquired RetinoschiThe term VEGFR3 also refers to nucleic acid sequences
sis, Hollenhorst Plaque, Idiopathic Central Serous Chorioreencoding any VEGFR3 protein, peptide, or polypeptide havtinopathy, Macular Hole, Presumed Ocular Histoplasmosis
ing VEGFR3 activity.
Syndrome, Retinal Macroaneursym, Retinitis Pigmentosa,
In one embodiment, double stranded nucleic acid molecule 15 Retinal Detachment, Hypertensive Retinopathy, Retinal Pigof the invention is amicroRNA (miRNA). By "micro RNA" or
ment Epithelium (RPE) Detachment, Papillophlebitis, Ocu"miRNA" is meant, a small double stranded RNA that regular Ischemic Syndrome, Coats' Disease, Leber's Miliary
lates the expression of target messenger RNAs either by
Aneurysm, Conjunctival Neoplasms, Allergic Conjunctivitis,
mRNA cleavage, translational repression/inhibition or hetVernal Conjunctivitis, Acute Bacterial Conjunctivitis, Allererochromatic silencing (see for example Ambros, 2004, 20 gic Conjunctivitis & Vernal Keratoconjunctivitis, Viral ConNature, 431, 350-355; Bartel, 2004, Cell, 116, 281-297;
junctivitis, Bacterial Conjunctivitis, Chlamydia! & GonococCullen, 2004, Virus Research., 102, 3-9; He eta!., 2004, Nat.
cal Conjunctivitis, Conjunctival Laceration, Episcleritis,
Scleritis, Pingueculitis, Pterygium, Superior Limbic KeratoRev. Genet., 5, 522-531; and Ying et a!., 2004, Gene, 342,
conjunctivitis (SLK ofTheodore ), Toxic Conjunctivitis, Con25-28). In one embodiment, the microRNA of the invention,
has partial complementarity (i.e., less than 100% comple- 25 junctivitis with Pseudomembrane, Giant Papillary Conjuncmentarity) between the sense strand or sense region and the
tivitis, Terrien's Marginal Degeneration, Acanthamoeba
Keratitis, Fungal Keratitis, Filamentary Keratitis, Bacterial
antisense strand or antisense region of the miRNA molecule
Keratitis, Keratitis Sicca/Dry Eye Syndrome, Bacterial
or between the antisense strand or antisense region of the
Keratitis, Herpes Simplex Keratitis, Sterile Corneal InfilmiRNA and a corresponding target nucleic acid molecule.
For example, partial complementarity can include various 30 trates, Phlyctenulosis, Corneal Abrasion & Recurrent Cormismatches or non-base paired nucleotides (e.g., 1, 2, 3, 4, 5
neal Erosion, Corneal Foreign Body, Chemical Burs, Epithelial Basement Membrane Dystrophy (EBMD), Thygeson's
or more mismatches or non-based paired nucleotides, such as
Superficial Punctate Keratopathy, Corneal Laceration, Salznucleotide bulges) within the double stranded nucleic acid
mann's Nodular Degeneration, Fuchs' Endothelial Dystromolecule, structure which can result in bulges, loops, or overhangs that result between the sense strand or sense region and 35 phy, Crystalline Lens Subluxation, Ciliary-Block Glaucoma,
the antisense strand or antisense region of the miRNA or
Primary Open-Angle Glaucoma, Pigment Dispersion Syndrome and Pigmentary Glaucoma, Pseudoexfoliation Synbetween the antisense strand or antisense region of the
drome and Pseudoexfoliative Glaucoma, Anterior Uveitis,
miRNA and a corresponding target nucleic acid molecule.
Primary Open Angle Glaucoma, Uveitic Glaucoma & GlauIn another embodiment, the compounds, compositions,
and methods provided herein have therapeutic applications. 40 comatocyclitic Crisis, Pigment Dispersion Syndrome & PigFor example, a compound, or composition that includes the
mentary Glaucoma, Acute Angle Closure Glaucoma, Antecompound, can be administered to a subject in order to regurior Uveitis, Hyphema, Angle Recession Glaucoma, Lens
late the bioavailability or biological activity of VEGF or
Induced Glaucoma, Pseudoexfoliation Syndrome and Pseudoexfoliative Glaucoma, Axenfeld-Rieger Syndrome,
PIGF. Accordingly, a compound provided herein is believed
to find therapeutic use for treating mammals via stimulation 45 Neovascular Glaucoma, Pars Planitis, Choroidal Rupture,
Duane's Retraction Syndrome, Toxic/Nutritional Optic Neuor inhibition of growth and/or differentiation and/or activation of cells susceptible to stimulation by VEGF and/or PIGF.
ropathy, Aberrant Regeneration of Cranial Nerve III, Intracranial Mass Lesions, Carotid-Cavernous Sinus Fistula, AnteExogenous compound may be administered to a patient in
these circumstances. A compound of the invention is clearly
rior Ischemic Optic Neuropathy, Optic Disc Edema &
useful insofar as it can be administered to a subject having so Papilledema, Cranial Nerve III Palsy, Cranial Nerve IV Palsy,
depressed levels (e.g., through sequestration with an inactiCranial Nerve VI Palsy, Cranial Nerve VII (Facial Nerve)
vating agent) of biologically active endogenous VEGF or
Palsy, Horner's Syndrome, Internuclear Ophthalmoplegia,
PIGF. Such depressed levels are generally the result ofVEGF
Optic Nerve Head Hypoplasia, Optic Pit, Tonic Pupil, Optic
or PIGF interactions with an inactivating agent. An agentNerve Head Drusen, Demyelinating Optic Neuropathy (Opgrowth factor complex forms which negatively impacts the 55 tic Neuritis, Retrobulbar Optic Neuritis), Amaurosis Fugax
and Transient Ischemic Attack, Pseudotumor Cerebri, Pitubioavailability or biological activity ofVEGF and/or PIGF.
itary Adenoma, Molluscum Contagiosum, Canaliculitis, VerCompounds provided herein reverse the effect of the inactiruca and Papilloma, Pediculosis and Pthiriasis, Blepharitis,
vating agent by inhibiting, preventing or disrupting the forHordeolum, Preseptal Cellulitis, Chalazion, Basal Cell Carmation of such a complex.
Accordingly, the compounds, compositions and methods 60 cinoma, Herpes Zoster Ophthalmicus, Pediculosis & Phthiriprovided herein can be used to treat conditions associated
asis, Blow-out Fracture, Chronic Epiphora, Dacryocystitis,
with decreased vascularity. For example, tissue that requires
Herpes Simplex Blepharitis, Orbital Cellulitis, Senile Entrovascularization, neovascularization and/or revascularization
pion, and Squamous Cell Carcinoma.
By "pre-eclampsia" is meant the multi-system disorder
of in a subject can be treated by a compound, composition or
method provided herein. Such conditions include ocular dis- 65 that is characterized by hypertension with proteinuria or
orders, preeclampsia, cerebrovascular disorders, cardiovasedema, or both, glomerular dysfunction, brain edema, liver
cular disorders, and wound healing disorders.
edema, or coagulation abnormalities due to pregnancy or the
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influence of a recent pregnancy. All forms of pre-eclampsia,
such as premature, mild, moderate, and severe pre-eclampsia
are included in this definition. Pre-eclampsia generally
occurs after the 20th week of gestation. Pre-eclampsia is
generally defined as some combination of the following
symptoms: (1) a systolic blood pressure (BP)>140 mmHg
and a diastolic BP>90 mmHg after 20 weeks gestation (generally measured on two occasions, 4-168 hours apart), (2)
new onset proteinuria (by dipstik on urinanaysis, >300 mg of
protein in a 24-hour urine collection, or a single random urine
sample having a protein/creatinine ratio>0.3), and (3) resolution of hypertension and proteinuria by 12 weeks postpartum. Severe pre-eclampsia is generally defined as (1) a diastolic BP> 110 mmHg (generally measured on two occasions,
4-168 hours apart) or (2) proteinuria characterized by a measurement of3.5 g or more protein in a 24-hoururine collection
or two random urine specimens with at least 3+protein by
dipstick. In pre-eclampsia, hypertension and proteinuria generally occur within seven days of each other. In severe preeclampsia, severe hypertension, severe proteinuria and
HELLP syndrome (hemolysis, elevated liver enzymes, low
platelets) or eclampsia can occur simultaneously or only one
symptom at a time. HELLP syndrome is characterized by
evidence of thrombocytopenia (<1 00000 cells/ul), increased
LDH (>600 IU/L) and increasedAST (>70 IU/L). Occasionally, severe pre-eclampsia can lead to the development of
seizures. This severe form of the syndrome is referred to as
"eclampsia." Eclampsia can also include dysfunction or damage to several organs or tissues such as the liver (e.g., hepatocellular damage, periportal necrosis) and the central nervous system (e.g., cerebral edema and cerebral hemorrhage).
The etiology of the seizures is thought to be secondary to the
development of cerebral edema and focal spasm of small
blood vessels in the kidney.
Several factors have been-reported to have an association
with fetal and placental development and, more specifically,
with pre-eclampsia. They include vascular endothelial
growth factor (VEGF), soluble Flt-1 receptor (sF!t-1), and
placental growth factor (PIGF). As previously noted, VEGF is
an endothelial cell-specific mitogen, an angiogenic inducer,
and a mediator of vascular permeability. VEGF has also been
shown to be important for glomerular capillary repair. VEGF
binds as a homodimer to one of two homologous membranespanning tyrosine kinase receptors, the fms-like tyrosine
kinase (Flt-1) and the kinase domain receptor (KDR), which
are differentially expressed in endothelial cells obtained from
many different tissues. Flt-1, but not KDR, is highly
expressed by trophoblast cells which contribute to placental
formation. PIGF is a VEGF family member that is also
involved in placental development. PIGF is expressed by
cytotrophoblasts and syncytiotrophoblasts and is capable of
inducing proliferation, migration, and activation of endothelial cells. PIGF binds as a homodimer to the Fit -1 receptor, but
not the KDR receptor. Both PIGF and VEGF contribute to the
mitogenic activity and angiogenesis that are critical for the
developing placenta.
By "cardiovascular disorders" is meant cardiovascular
abnormalities, such as arteria-arterial fistula, arteriovenous
fistula, cerebral arteriovenous malformations, congenital
heart defects, pulmonary atresia, and Scimitar Syndrome.
Congenital heart defects include, but are not limited to, aortic
coarctation, cortriatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent, ductus arteriosus, Ebstein's
anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great
vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such as aor-

topulmonary septal defect, endocardial cushion defects,
Lutembacher's Syndrome, trilogy ofFallot, ventricular heart
septal defects.
Cardiovascular disorders also include, but are not limited
to, heart disease, such as arrhythmias, carcinoid heart disease,
high cardiac output, low cardiac output, cardiac tamponade,
endocarditis (including bacterial), heart aneurysm, cardiac
arrest, congestive heart failure, congestive cardiomyopathy,
paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right
ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardia! effusion, pericarditis
(including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar
Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.
Arrhythmias include, but are not limited to, sinus arrhythmia, atrial fibrillation, atrial fluner, bradycardia, extrastole,
Adams-Stokes Syndrome, bundle-branch block, sinoatrial
block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome,
Wolff-Parkinson-White syndrome, sick sinus syndrome,
tachycardias, and ventricular fibrillation. Tachycardias
include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular
nodal reentry tachycardia, ectopic atrial tachycardia, ectopic
junctional tachycardia, sinoatrial nodal reentry tachycardia,
sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.
Myocardial diseases include, but are not limited to, alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy,
Chagas
cardiomyopathy,
endocardial fibroelastosis,
endomyocardial fibrosis, Kearns Syndrome, myocardial reperfusion injury, and myocarditis.
Myocardial ischemias include, but are not limited to, coronary disease, such as angina pectoris, coronary aneurysm,
coronary arteriosclerosis, coronary thrombosis, coronary
vasospasm, myocardial infarction and myocardial stunning.
Cardiovascular diseases also include vascular diseases
such as aneurysms, angiodysplasia, angiomatosis, bacillary
angiomatosis, Rippel-Lindau Disease, Klippel-TrenaunayWeber Syndrome, Sturge-Weber Syndrome, angioneurotic
edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular disorders, diabetic angiopathies, diabetic retinopathy, embolisms,
thrombosis, erythromelalgia, hemorrhoids, hepatic vena-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary vena-occlusive
disease, Raynaud's disease, CREST syndrome, retinal vein
occlusion, Scimitar syndrome, superior vena cava syndrome,
telangiectasia, atacia telangiectasia, hereditary hemorrhagic
telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.
Aneurysms include, but are not limited to, dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.
Arterial occlusive diseases include, but are not limited to,
arteriosclerosis, intermittent claudication, carotid stenosis,
fibromuscular dysplasias, mesenteric vascular occlusion,
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Moyamoya disease, renal artery obstruction, retinal artery
ing. In a similar fashion, the compound can be used in plastic
occlusion, and thromboangiitis obliterans.
surgery when reconstruction is required following a bum or
Cerebrovascular disorders include, but are not limited to,
other trauma, or for cosmetic purposes.
carotid artery diseases, cerebral amyloid angiopathy, cerebral
Angiogenesis is also important in keeping wounds clean
aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral
and non-infected. The compound can therefore be used in
arteriovenous malformation, cerebral artery diseases, cereassociation with general surgery and following the repair of
bral embolism and thrombosis, carotid artery thrombosis,
cuts and lacerations. It is particularly useful in the treatment
sinus thrombosis, Wallenberg's syndrome, cerebral hemorof abdominal wounds with a high risk of infection. Neovasrhage, epidural hematoma, subdural hematoma, subaraxhcularization is also key to fracture repair, since blood vessels
noid hemorrhage, cerebral infarction, cerebral ischemia (in- 10 develop at the site of bone injury. Administration of the comeluding transient), subclavian steal syndrome, periventricular
pound to the site of a fracture is therefore another utility.
In cases where the compound is being used for topical
leukomalacia, vascular headache, cluster headache,
wound healing, as described above, it may be administered by
migraine, and vertebrobasilar insufficiency.
any of the routes described below for the re-endothelializaEmbolisms include, but are not limited to, air embolisms,
anmiotic fluid embolisms, cholesterol embolisms, blue toe 15 tion of vascular tissue, or more preferably by topical means.
In these cases, it will be administered as either a solution,
syndrome, fat embolisms, pulmonary embolisms, and thromoboembolisms. Tbrombosis include, but are not limited to,
spray, gel, cream, ointment, or dry powder directly to the site
coronary thrombosis, hepatic vein thrombosis, retinal vein
of injury. Slow-release devices directing the compound to the
occlusion, carotid artery thrombosis, sinus thrombosis, Walinjured site will also be used. In topical applications, the
lenberg's syndrome, and thrombophlebitis.
20 compound will be applied at a concentration ranging from
Ischemic disorders include, but are not limited to, cerebral
about 50 to 1,000 ug/mL, either in a single application, or in
ischemia, ischemic colitis, compartment syndromes, anterior
dosing regimens that are daily or every few days for a period
compartment syndrome, myocardial ischemia, reperfusion
of one week to several weeks. Generally, the amount of topiinjuries, and peripheral limb ischemia. Vasculitis includes,
cal formulation administered is that which is sufficient to
but is not limited to, aortitis, arteritis, Behcet's Syndrome, 25 apply from about 0.1 to 100 ug/cm2 of the compound, based
Churg-Strauss Syndrome, mucocutaneous lymph node synon the surface area of the wound.
drome, thromboangiitis obliterans, hypersensitivity vasculiThe compound can be used as a post-operative wound
tis, Schoenlein-Henoch purpura, allergic cutaneous vasculihealing agent in balloon angioplasty, a procedure in which
tis, and Wegener's granulomatosis.
vascular endothelial cells are removed or damaged, together
By "wound healing" is meant any disorder, disease or 30 with compression of atherosclerotic plaques. The compound
injury associated with a tissue that would benefit from
can be applied to inner vascular surfaces by systemic or local
increased vascularization. Accordingly, "wound healing"
intravenous application either as intravenous bolus injection
encompasses facilitating angiogenesis in the context vascuor infusions. If desired, the compound can be administered
larization of, for example, grafts, organ transplantation, or
over time using a micrometering pump. Suitable composiany other activity associated with tissue regeneration. Various 35 tions for intravenous administration comprise the compound
in an amount effective to promote endothelial cell growth and
potential therapeutic uses of a compound include those in
a parenteral carrier material. The compound can be present in
which increasing the bioavailability of VEGF or PlGF is
the composition over a wide range of concentrations, for
useful. Examples of these include uses associated with the
vascular endothelium, such as the treatment of traumata to the
example, from about 50 ug/mL to about 1,000 ug/mL using
vascular network, in view of the demonstrated rapid promo- 40 injections of 3 to 10 mL per patient, administered once or in
tion by VEGF of the proliferation of vascular endothelial cells
dosing regimens that allow for multiple applications. Any of
that would surround the traumata. Examples of such traumata
the known parenteral carrier vehicles can be used, such as
normal saline or 5-10% dextrose.
that could be so treated include, but are not limited to, surgical
incisions, particularly those involving the heart, wounds,
The compound can also be used to promote endothelialincluding lacerations, incisions, and penetrations of blood 45 ization in vascular graft surgery. In the case of vascular grafts
vessels, and surface ulcers involving the vascular endotheusing either transplanted vessels or synthetic material, for
lium such as diabetic, hemophiliac, and varicose ulcers. Other
example, the compound can be applied to the surfaces of the
physiological conditions that could be improved based on the
graft and/or at the junctions of the graft and the existing
selective mitogenic character of the compound are also
vasculature to promote the growth of vascular endothelial
included herein.
so cells. For such applications, the compound can be applied
For the traumatic indications referred to above, the comintravenously as described above for balloon angioplasty or it
can be applied directly to the surfaces of the graft and/or the
pound will be formulated and dosed in a fashion consistent
with good medical practice taking into account the specific
existing vasculature either before or during surgery.
By "Pharmaceutically acceptable composition" or "theradisorder to be treated, the condition of the individual patient,
the site of delivery of the compound, the method of adminis- 55 peutic formulation" is meant a carrier that is physiologically
tration, and other factors known to practitioners. Accordingly,
acceptable to the treated mammal while retaining the therathe compound can be included in a composition, such as a
peutic properties of the compound with which it is adminispharmaceutically-acceptable composition, for administratered. One exemplary pharmaceutically acceptable carrier
substance is physiological saline. Other physiologically
tion to the site of trauma.
Additional indications for compounds provided herein 60 acceptable carriers and their formulations are known to one
include the treatment of full-thickness wounds such as dermal
skilled in the art and described, for example, in Remington's
Pharmaceutical Sciences, (20th edition), ed. A. Gennaro,
ulcers, including the categories of pressure sores, venous
ulcers, and diabetic ulcers, as well as of full-thickness bums
2000, Lippincott, Williams & Wilkins, Philadelphia, Pa.
Such compositions are prepared for storage by mixing
and injuries where angiogenesis is required to prepare the
bum or injured site for a skin graft or flap. In this case the 65 compound having the desired degree of purity with optional
compound is either applied directly to the site or it is used to
physiologically acceptable carriers, excipients, or stabilizers
soak the skin or flap that is being transplanted prior to graft(Remington's Pharmaceutical Sciences, 16th edition, Osol,
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A., Ed., [1980]), in the form oflyophilized cake or aqueous
solutions. Acceptable carriers, excipients, or stabilizers are
nontoxic to recipients at the dosages and concentrations
employed, and include buffers such as phosphate, citrate, and
other organic acids; antioxidants including ascorbic acid; low
molecular weight (less than about 10 residues) polypeptides;
proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone;
amino acids such as glycine, glutamine, asparagine, arginine,
or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, marmose, or dextrins; chelating
agents such as EDTA; sugar alcohols such as mannitol or
sorbitol; salt-forming counter-ions such as sodium; and/or
non-ionic surfactants such as Tween, Pluronics or polyethylene glycol (PEG).
The compound also may be entrapped in microcapsules
prepared, for example, by coacervation techniques or by
interfacial polymerization (for example, hydroxymethylcellulose or gelatin-microcapsules and poly-[ methylmethacylate] microcapsules, respectively), in colloidal drug delivery
systems (for example, liposomes, albumin microspheres,
microemulsions, nano-particles, and nanocapsules), or in
macroemulsions.
In general, a compound to be used for in vivo administration must be sterile. This is readily accomplished by filtration
through sterile filtration membranes, prior to or following
lyophilization and reconstitution. compound ordinarily will
be stored in lyophilized form or in solution.
Therapeutic compound compositions generally are placed
into a container having a sterile access port, for example, an
intravenous solution bag or vial having a stopper pierceable
by a hypodermic injection needle.
The route of compound administration is in accord with
known methods, e.g., those routes set forth above for specific
indications, as well as the general routes of injection or infusian by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial, or intralesional means, or sustained release systems as noted below. A compound provided
herein can be administered continuously by infusion or by
bolus injection. Generally, where the disorder permits, one
should formulate and dose the compound for site-specific
delivery. This is convenient in the case of wounds and ulcers.
Suitable examples of sustained-release preparations include
semi-permeable matrices of solid hydrophobic polymers containing the protein, which matrices are in the form of shaped
articles, e.g., films, or microcapsules. Examples of sustainedrelease matrices include polyesters, hydro gels [e.g., poly(2hydroxyethyl-methacrylate) as described by Langer eta!., J.
Biomed. Mater. Res., 15:167, 1981 and Langer, Chern. Tech.,
12:98, 1982 or poly(vinylalcohol)], polylactides (U.S. Pat.
No. 3,773,919, EP 58,481), copolymers of L-glutamic acid
and gamma ethyl-L-glutamate (Sidman eta!., Biopolymers,
22:547, 1983), non-degradable ethylene-vinyl acetate
(Langer et a!., supra), degradable lactic acid-glycolic acid
copolymers such as the Lupron Depot™ (injectable microspheres composed oflactic acid-glycolic acid copolymer and
leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid
(EP 133,988).
While polymers such as ethylene-vinyl acetate and lactic
acid-glycolic acid enable release of molecules for over 100
days, certain hydrogels release proteins for shorter time periods. When encapsulated compounds remain in the body for
an extended period of time, they may denature or aggregate as
a result of exposure to moisture at 37° C., resulting in a loss of
biological activity. Rational strategies can be devised for
nucleic acid and/or protein stabilization depending on the
mechanism involved.

Sustained-release compound compositions also include
liposomally entrapped compound. Liposomes containing
compound are prepared by methods known per se: DE 3,218,
121; Epsteinet a!., Proc. Natl.Acad. Sci. USA, 82:3688-3692
(1985); Hwang eta!., Proc. Nat!. Acad. Sci. USA, 77:40304034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949;
EP 142,641; Japanese patent application 83-118008; U.S.
Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily the liposomes are of the small (about 200-800 Angstroms) nnilamellar type in which the lipid content is greater
than about 30 mol % cholesterol, the selected proportion
being adjusted for the optimal compound therapy.
When applied topically, the compound is suitably combined with other ingredients, such as carriers and/or adjuvants. There are no limitations on the nature of such other
ingredients, except that they must be pharmaceutically
acceptable and efficacious for their intended administration,
and carmot degrade the activity of the active ingredients of the
composition. Examples of suitable vehicles include ointments, creams, gels, or suspensions, with or without purified
collagen. The compositions also may be impregnated into
transdermal patches, plasters, and bandages, preferably in
liquid or semi-liquid form.
For obtaining a gel formulation, the compound formulated
in a liquid composition may be mixed with an effective
amount of a water-soluble polysaccharide or synthetic polymer such as PEG to form a gel of the proper viscosity to be
applied topically. The polysaccharide that may be used
includes, for example, cellulose derivatives such as etherified
cellulose derivatives, including alkyl celluloses, hydroxyalkyl celluloses, and alkylhydroxyalky celluloses, for
example, methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxypropyl methylcellulose, and
hydroxypropyl cellulose; starch and fractionated starch; agar;
alginic acid and alginates; gum arabic; pullullan; agarose;
carrageenan; dextrans; dextrins; fructans; inulin; mannans;
xylans; arabinans; chitosans; glycogens; glucans; and synthetic biopolymers; as well as gums such as xanthan gum;
guar gum; locust bean gum; gum arabic; tragacanth gum; and
karaya gum; and derivatives and mixtures thereof. The preferred gelling agent herein is one that is inert to biological
systems, nontoxic, simple to prepare, and not too runny or
viscous, and will not destabilize the compound held within it.
Preferably the polysaccharide is an etherified cellulose
derivative, more preferably one that is well defined, purified,
and listed in USP, e.g., methylcellulose and the hydroxyalkyl
cellulose derivatives, such as hydroxypropyl cellulose,
hydroxyethyl cellulose, and hydroxypropyl methylcellulose.
Most preferred herein is methylcellulose.
The polyethylene glycol useful for gelling is typically a
mixture of! ow and high molecular weight PEGs to obtain the
proper viscosity. For example, a mixture of a PEG of molecular weight 400-600 with one of molecular weight 1500 would
be effective for this purpose when mixed in the proper ratio to
obtain a paste.
The term "water soluble" as applied to the polysaccharides
and PEGs is meant to include colloidal solutions and dispersions. In general, the solubility of the cellulose derivatives is
determined by the degree of substitution of ether groups, and
the stabilizing derivatives useful herein should have a sufficient quantity of such ether groups per anhydroglucose nnit in
the cellulose chain to render the derivatives water soluble. A
degree of ether substitution of at least 0.35 ether groups per
anhydroglucose unit is generally sufficient. Additionally, the
cellulose derivatives may be in the form of alkali metal salts,
for example, the Li, Na, K, orCs salts.
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If methylcellulose is employed in the gel, preferably it
comprises about 2-5%, more preferably about 3%, of the gel
and the compound is present in an amount of about 300-1000
mg per ml of gel.
An effective amount of compound to be employed therapeutically will depend, for example, upon the therapeutic
objectives, the route of administration, and the condition of
the patient. Accordingly, it will be necessary for the therapist
to titer the dosage and modifY the route of administration as
required to obtain the optimal therapeutic effect. Typically,
the clinician will administer the compound until a dosage is
reached that achieves the desired effect. A typical daily dosage for systemic treatment might range from about 1 ug/kg to
up to 10 mg/kg or more, depending on the factors mentioned
above. As an alternative general proposition, the compound is
formulated and delivered to the target site or tissue at a dosage
capable of establishing in the tissue a compound level greater
than about 0.1 ng/cc up to a maximum dose that is efficacious
but not unduly toxic. This intra-tissue concentration should
be maintained if possible by continuous infusion, sustained
release, topical application, or injection at empirically determined frequencies. The progress of this therapy is easily
monitored by conventional assays.
It is within the scope hereof to combine "compound
therapy" with other novel or conventional therapies (e.g.,
growth factors such as VEGF, PlGF, acidic or basic fibroblast
growth factor (aFGF or bFGF, respectively), platelet-derived
growth factor (PDGF), insulin-like growth factor (IGF-I or
IGF-II), nerve growth factor (NGF), anabolic steroids, EGF
or TGF -alpha) for enhancing the activity of any of the growth
factors, including the compound, in promoting cell proliferation and repair.
It is not necessary that such co-treatment drugs be included
per se in the compositions of this invention, although this will
be convenient where such drugs are proteinaceous. Such
admixtures are suitably administered in the same manner and
for the same purposes as the compound used alone. The useful
molar ratio of compound to such secondary growth factors is
typically 1:0.1-10, with about equimolar amounts being preferred.
As discussed throughout the present specification, the
inventors have identified a unique interaction between growth
factors and inactivating agents in ocular tissue. The interaction effectively results in the inactivation of the growth factors
by sequestration in complexes. In view of this discovery, the
present specification not only provides novel compounds for
regulating the bioavailability of growth factors, but also provides mechanisms for identifying additional compounds
which modulate such interactions. Accordingly, based on
these discoveries, any number of methods are available for
carrying out screening assays to identify new candidate compounds that alter the ability of an inactivating agent to sequester a growth factor.
Thus, in another embodiment, provided herein are methods
of identifying a compound that regulates the bioavailability or
biological activity of VEGF or PlGF in vivo or in situ. In
general, the method includes contacting corneal tissue with a
test compound that regulates, or is believed to regulate, the
expression of a VEGF or PlGF inactivating agent, or the
ability of the VEGF or PlGF inactivating agent to bind to
VEGF or PlGF. The bioavailability or biological activity of
VEGF or PlGF can be measured and the compound identified
by its effect on the bioavailability or biological activity of
VEGF or PlGF.
There is provided a method for screening candidate compounds that modulate the ability of an inactivating agent to
interact with VEGF or PlGF thereby promoting vasculariza-

tion in a tissue, such as ocular or placental tissue. Preferably,
the test compound prevents, inhibits or disrupts the ability of
an FLT gene product to interact with VEGF or PlGF and
inhibit or antagonize VEGF or PlGF activity. In this aspect of
the invention, ocular tissue associated with, or derived from,
a test animal, such as a mouse, rat, rabbit, monkey, pig, etc.
can be used in the screening method. The candidate drug or
test compound is administered to the ocular tissue at various
times and at various locations (as described throughout the
specification). Subsequently, the tissue is monitored for the
appearance of neovascularization, or for an increase on the
bioavailability or biological activity of a growth factor such as
VEGF.
Exemplary test compounds include siNA molecules that
are active in mediating RNA interference against a VEGF
and/or PlGF inactivating agent. Additional exemplary test
compounds include organic molecules, peptides, peptide
mimetics, polypeptides, nucleic acids, and antibodies that
bind to a soluble inactivating agent. Optionally, compounds
identified in any of the assays described herein may be confirmed as useful in an assay for compounds that increase the
bioavailability or biological activity ofVEGF or PlGF.
In general, compounds capable of decreasing the inactivating activity of an agent can be identified from large libraries
of both natural product or synthetic (or semi-synthetic)
extracts or chemical libraries or from polypeptide or nucleic
acid libraries, according to methods known in the art. Those
skilled in the field of drug discovery and development will
understand that the precise source of test extracts or compounds is not critical to the screening procedure(s) of the
invention. Compounds used in screens may include known
compounds (for example, known therapeutics used for other
diseases or disorders). Alternatively, virtually any number of
unknown chemical extracts or compounds can be screened
using the methods described herein. Examples of such
extracts or compounds include, but are not limited to, plant-,
fungal-, prokaryotic- or animal-based extracts, fermentation
broths, and synthetic compounds, as well as modification of
existing compounds. Numerous methods are also available
for generating random or directed synthesis (e.g., semi-synthesis or total synthesis) of any number of chemical compounds, including, but not limited to, saccharide-, lipid-, peptide-, and nucleic acid-based compounds. Synthetic
compound libraries are commercially available from Brandon Associates (Merrimack, N.H.) and Aldrich Chemical
(Milwaukee, Wis.). Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant, and animal
extracts are commercially available from a number of
sources, including Biotics (Sussex, UK), Xenova (Slough,
UK), Harbor Branch Oceangraphics Institute (Ft. Pierce,
Fla.), and PharmaMar, U.S.A. (Cambridge, Mass.). In addition, natural and synthetically produced libraries are produced, if desired, according to methods known in the art, e. g.,
by standard extraction and fractionation methods. Furthermore, if desired, any library or compound is readily modified
using standard chemical, physical, or biochemical methods.
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The invention is illustrated in the following examples,
which are provided by way of illustration and are not intended
to be limiting.
Corneal avascularity is required for optical clarity and optimal vision and has enabled the cornea to become the lead
platform for validating pro- and anti -angiogenic strategies for
myriad disorders. Yet the molecular underpinnings of the
avascular phenotype have until now remained obscure and are
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all the more remarkable given the presence of vascular endothelial growth factor (VEGF)-A, a potent stimulator of angiogenesis, in the cornea and its proximity to vascularized tissues. The present studies show that the cornea expresses
soluble VEGF receptor-! (sVEGFR-1; 1 also known as sflt-1)
and that suppression of this endogenous VEGF-A trap by
neutralizing antibodies, RNA interference, or Cre-lox mediated gene disruption abolishes corneal avascularity in mice.
The spontaneously vascularized corneas of corn! and
Pax6+1- mice and Pax6+1- patients with aniridia are deficient
in sflt-1. Recombinant sflt-1 administration rescues corneal
avascularity in corn! and Pax6+1- mice. Manatees, the only
known creatures to uniformly have vascularized corneas, do
not express sflt-1, whereas the avascular corneas of dugongs,
also members of the order Sirenia, elephants, the closest
extant terrestrial phylogenetic relatives of manatees, and
other marine mammals (dolphins, whales) contain sflt-1,
indicating a crucial, evolutionarily conserved role. The recognition that sflt-1 is essential to shielding vascular apartheid
in the cornea provides a platform for modulating angiogenesis and treating neovascular diseases.
Despite its widespread use as a readout template, the
molecular foundations of corneal avascularity remain nebulous. In the last decade numerous anti-angiogenic molecules
such as angiostatin, endostatin, interleukin-1 receptor antagonist, pigment epithelium derived factor, and thrombospondins were identified in the cornea (reviewed in Chang et a!.,
Curr. Opin. Ophthalmol. 12:242, 2001), leading to recognition of their tumor suppressive, atherosclerotic plaque growth
inhibitory, or wound healing modulatory roles. None of these
molecules, however, are singly requisite for corneal avascularity because mice deficient in any of them retain normal
corneal phenotypes, engendering the view of multiply redundant mechanisms of corneal avascularity. The search for
angiogenesis inhibitors to treat atherosclerosis, cancer, diabetic kidney and retina damage, macular degeneration, and
rheumatoid arthritis often relies on initial efficacy testing in
the cornea for it is exquisitely devoid ofblood vessels despite
being surrounded by the highly vascular conjunctiva (FIG. 1,
panel A). The cornea is ideal for understanding the ability of
tissues to demarcate vascular ingrowth and identifYing efficacy of therapies against known angiogenic stimuli.
The present studies have determined, for the first time, that
the cornea contained VEGF -A, but nearly all of it was bound
(FIG. 1, panel B). To reconcile the paradoxical presence of
this potent pro-angiogenic molecule in an avascular tissue, a
counterbalancing expression of sflt-1 was identified. sflt-1 is
an alternatively spliced secreted isoform of membrane bound
flt-1 (mbflt-1 ), a cell surface receptor. sflt-1 lacks the transmembrane (tm) and tyrosine kinase (tk) domains and can act
as a manacle for VEGF-A (Kendall & Thomas, Proc. Nat!.
Acad. Sci. USA, 90:10705, 1993). sflt-1 mRNAandprotein
were identified in the cornea (FIG. 1, panels C-G); in contrast,
mbflt-1 was present in the conjunctiva but not detectable in
the cornea (FIG. 1, panel G). sflt-1 was present extracellularly. In vivo interaction between sflt-1 and VEGF-A was
confirmed by immunoprecipitation (FIG. 1, panel H) and
corroborated by immunostaining.
sflt-1 preservation of corneal avascularity was confirmed in
mice. First, corneal injections of neutralizing antibody
against flt-1 were performed with fellow eyes receiving isotype control antibody. Eyes treated with blocking antibody
consistently developed corneal vascularization (CV) from the
limbus within 1 day, whereas those treated with control antibody did not (P<O.OOl). Free VEGF-A was greater in antiflt-1 antibody-treated corneas than in control treated corneas,
indicating that sequestration ofVEGF-A by sflt-1 maintains

corneal avascularity. This was confirmed by demonstrating
that concomitantly treating corneas with neutralizing antiVEGF-A antibody, but not with isotype-control antibody,
prevented CV induced by the anti-flt-1 antibody (P=0.029).
Because the anti-flt-1 antibody would theoretically block
ligand-binding ofbothmbflt-1 and sflt-1 (although the former
is undetectable in the cornea), this antibody was tested in flt-1
tyrosine kinase_;_ (flt-1 tk_ 1_) mice, which are deficient in
receptor ligation induced signaling. The anti-fit -1 antibody,
but not control, induced CV in flt-1 tk_;_ eyes as well
(P=0.029), indicating that the vascular phenotype resulted
from suppression of sflt-1 function and not interference with
flt-1 signaling. Subconjunctival injection of anti-flt-1 antibody, which eliminates the confounding effect of corneal
trauma, also elicited CV (P=O.OOS).
In another embodiment, sflt-1 expression was conditionally regulated by genomic deletion. sflt-1 expression was
suppressed by conditional Cre-lox mediated gene ablation
because flt-1 deletion is lethal. Corneal injection of plasmid
encoding Cre recombinase (pCre), but not of pNull, induced
CV in flt-1 1oxP!loxP mouse eyes (P<O.OOl) within 2 days. Cre
expression was accompanied by significantly reduced sflt-1
and increased free VEGF-A. Neither plasmid induced CV in
wild-type mice. To avoid injection trauma, a cell permeable
enzymatically active Cre containing a nuclear localization
sequence (NLS-Cre) was delivered to the cornea by topical
eye drops (FIG. 2, panels A-D). NLS-Cre, but not NLS-~
galactosidase, induced CV in flt-1 1oxP!loxP mouse eyes
(P<O.OOl) within 2 days (FIG. 2, panels E and F). Neither
NLS-enzyme induced CV in wild-type mice (FIG. 2, panels
GandH).
In another embodiment, sflt-1 expression was regulated
using RNA interference (RNAi) via corneal injection of plasmid expressing a short hairpin RNA (shRNA) targeted
against a sequence in the unique carboxyl-terminus region of
sflt-1 (pshRNA-sflt-1 ). The control was plasmid expressing a
shRNA targeted against a sequence in the unique carboxylterminus region of mbflt-1 not present in sflt-1 (pshRNAmbflt-1). pshRNA-sflt-1, but not pshRNA-mbflt-1, substantially reduced both sflt-1 mRNA and protein, indicating that
knockdown was through RNAi (FIG. 3, panels A and B), and
increased free VEGF-A (FIG. 3, panel C), corroborating the
thesis that sflt-1 sequesters VEGF -A to maintain physiological avascularity. pshRNA-sflt-1, but not pshRNA-mbflt-1,
consistently induced CV within 3 days after injection
(P<O.OOOl) (FIG. 3, panels D-F). pshRNA-sflt-1 also induced
CV in mice systemically depleted of macrophages and neutrophils by clodronate liposomes and anti-Gr-1 antibody,
indicating that CV was not induced by infiltration of inflammatory cells and their delivery of VEGF-A. Further,
pshRNA-sflt-1 did not elevate VEGF-A mRNA.
In addition to sflt-1, the transmembrane domain of flt-1
(flt-1-TM) also can trap VEGF-A. flt-1 tk_;_ mice (n>60),
which retain expression of sflt-1 and flt-1-TM, have avascular
corneas just as wild-type mice. pshRNA-sflt-1, but not
pshRNA-mbflt-1, induced CV in flt-1 tk_;_ eyes (P=0.029)
just as in wild-type eyes, indicating that sflt-1 and not flt-1TM is required for corneal avascularity.
Apart from VEGF-A, sflt-1 also binds VEGF-B and placenta growth factor (PlGF). Expression of these alternate
ligands in mouse corneas was much less than that ofVEGFA. Moreover, pshRNA-sflt-1, but not pshRNA-mbflt-1,
induced CV both in Vegfb_;_ (P=0.029) and Plgr-1(P<O.OOOl) mice, supporting the contention that CV results
from desequestration ofVEG F-A from sflt -1. Direct evidence
for this assertion was obtained by demonstrating that CV
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induced by pshRNA-sflt-1 in wild-type mice was prevented
by a neutralizing anti-VEGF-A antibody but not by isotypecontrol antibody (P=0.008).
pshRNAs can inhibit gene expression nonspecifically via
interferon (IFN)-mediated responses; however, pshRNA -sflt1 induced CV in Ifnarl_;_ and Ifng_;_ mice just as in wildtype mice, indicating that CV was not attributable to IFN
response effectors. To examine whether other off-target
effects might be responsible for CV induced by pshRNA-sflt1, a p 2 shRNA-sflt-1 targeted against a different sequence in
the unique carboxyl terminus region of sflt-1 was synthesized. Corneal injection of p 2 shRNA-sflt-1 also induced CV
in wild-type mice, making it unlikely that off-target effects,
which are sequence-specific and not target-specific, were
responsible for loss of corneal avascularity.
To confirm that CV induced by pshRNA-sflt-1 was mechanistically linked to sflt-1 knockdown, a plasmid coding for a
"hardened-target" version of sflt-1 (psflt-1 *) containing
seven translationally silent wobble position mutations rendering expressed sflt-1 refractory to pshRNA-sflt-1 was developed. psflt-1 *,but not psflt-1, prevented suppression of sflt-1
and CV development in eyes treated with pshRNA-sflt-1
(P=0.008); this functional control definitively established that
the angiogenic phenotype was due to RNAi -mediated knockdown of sflt-1. Genetic, transcriptional, and protein-targeting
suppression of sflt -1 all induced CV, demonstrating that sflt -1
is the preeminent molecular defender of corneal avascularity.
The cornea remains avascular even in states of hypoxia
such as those induced by eyelid closure during sleep or coma,
and a variety of ischemic and occlusive disease states. We
examined VEGF-A and sflt-1 levels in corneas of mice
exposed to 8% 0 2 (comparable to corneal hypoxia during
sleep) for 24 hours. Despite profound hypoxia, these corneas
remained avascular. Although hypoxia can increase VEGF -A
production, free VEGF-A was not significantly elevated in
hypoxic corneas (11 ±23% greater than non-hypoxic corneas;
P=0.78). This was attributed to a 86±34% increase in sflt-1 in
hypoxic corneas (P=0.05), consistent with the presence of a
hypoxia-responsive element in the flt-1 gene. These data confirm an important protective role upon sflt-1 in maintaining
corneal avascularity during physiological hypoxia. In contrast, VEGF-A elevation without concomitant sflt-1 induction, modeled by injection of recombinant VEGF-A, was
reversed by recombinant sflt-1/Fc administration but not isotype control IgG/Fc, confirming its specificity.
The spontaneously vascularized corneas of corn! and
Pax6+1- mice were examined for the presence of sflt-1. Corneas of corn! and Pax6+1- mice, unlike those of their background strains, were deficient in sflt-1 (FIG. 4, panel A). It is
notable that both strains have abnormalities in their corneal
epithelium, the predominant source of sflt-1. sflt-1/Fc injection significantly reduced CV area in corn! and Pax6+1- mice
compared to both IgG/Fc treated and untreated corneas, both
conferring a significant role for sflt-1 in maintaining corneal
homeostasis and suggesting the potential to clinically rescue
CV. Although mutations in destrin, the protein altered in
corn! mice, have not been reported in humans, Pax6 mutations are present in patients with aniridia, who also have CV.
Interestingly aniridic patient corneas were deficient in sflt-1
compared to normal human corneas (FIG. 4, panel D).
Florida manatees (Trichechus manatus latirostris) are the
only organisms reported to uniformly have spontaneously
vascularized corneas. This phenotype was also observed in
the Antillean manatee (Trichechus manatus manatus). Interestingly neither manatee cornea expressed sflt-1 whereas the
avascular corneas of dugongs (Dugong dugan), which also
belong to order Sirenia, and of Asian (Elephas maxim us) and

African (Loxodanta africana) elephants, the closest extant
terrestrial phylogenetic relatives of manatees, did (FIG. 4,
panels E-G). The avascular corneas of other marine mammals
such as dolphins (bottlenose: Tursiops truncatus; Risso's:
Grampus griseus), and whales (Cuvier's beaked: Ziphius
cavirostris; fin: Balaenoptera physalus; melon-headed: Peponocephala electra) also contained sflt-1 (FIG. 4, panels H
and I). The correlation between sflt-1 expression and corneal
avascularity in diverse mammals supports an evolutionarily
conserved role for sflt-1 conferring the cloak of corneal avascularity. Unlike dolphin and elephant corneas (FIG. 4, panel
I), manatee corneas expressed mbflt-1, suggesting a splicing
switch potentially accounting for their vascularized state. The
teleological basis of the vascularized manatee cornea is
intriguing. The absence of corneal sflt-1 and potentially suboptimal vision might result from a non-deleterious mutation
in manatees as they live primarily in turbid waters. Unlike
dugongs which are strictly marine, manatees are believed to
be physiologically dependent on freshwater and CV could
protect against, or perhaps result from, irritations of this
hypotonic environment.
The presence of numerous anti-angiogenic molecules in
the cornea suggests multiply redundant mechanisms for
maintaining avascularity, which is essential for optical transparency and clear vision. Therefore the finding that neutralization or knockdown of sflt-1 alone abolishes corneal avascularity is surprising but consistent with the presence of
VEGF-A in the normal cornea. VEGF-A may be produced
and held in a sequestered state by the cornea as a readily
available store because this exposed tissue is susceptible to
injuries potentially requiring an angiogenic response. Alternatively it might be a vestigial residue of an evolutionary
requirement to provide blood to the eye that later required
biochemical compensation in the form of sflt-1 expression to
support improved vision.
The utilization of sflt-1 to regulate VEGF -A bioavailability
is conserved in other systems such as cyclic vascularization
and embryonic sprouting, and disturbances in this regulation
underlie preeclampsia. The present data identifY a new role
for sflt-1 in evolutionary establishment of optimal vision
resulting from and requiring optical clarity. Apart from trapping VEGF-A, sflt-1 can heterodimerize with mbflt-1 and
VEGFR-2. Although neither mbflt-1 nor VEGFR-2 is
expressed in the normal cornea (FIG. 1, panel G), such heterodimerization can modulate pathological CV. Other
mechanisms of regulating VEGF-A bioavailability, such as
matrix metalloproteinase-induced release, have been identified in a tumor angiogenesis model (Bergers eta!., Nat. Cell.
Bioi. 2:737, 2000).
The cornea has long been used as a readout platform to
assay anti-angiogenic therapy in oncology, cardiovascular
biology, and other fields. The recognition that sflt-1 is dominant in maintaining corneal avascularity directly impacts the
generalizability of this tissue in individual models. The
present data elucidates the immunologic privilege of the cornea as corneal avascularity is critical to the high success of
corneal allografts. The present findings also support the use of
sflt-1 in preventing or treating neovascularization. Furthermore, they illuminate its potential as a therapeutic target in
conditions where inducing angiogenesis in a sflt-1-rich
microenvironment might be beneficial, e.g., preeclampsia,
wound healing, stroke, and heart disease.
In vivo images were captured by CCD camera (Nikon)
under a dissecting microscope. Blood vessels were defined by
positive labeling with FITC-conjugated rat antibody against
mouse CD31 (1 :333; BD Pharmingen) and negative labeling
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with rabbit antibody against mouse LYVE-1 (1 :333; Abeam)
on corneal flat mounts as previously reported.
Neutralizing goat antibody (10 flg) against mouse flt-1
(R&D Systems), isotype control goat IgG (1 0 flg; Jackson
Immunoresearch), shRNAs (4 flg) against mbflt-1 or sflt-1,
psflt-1 (4 flg), psflt-1 * (4 flg), pCre (4 flg), pNull (4 flg),
rmVEGF-A 164 (20-500 ng; R&D Systems), sflt-1/Fc (5 flg;
R&D Systems), or isotype control IgGl/Fc (5 flg; Jackson
Immunoresearch) were injected (2 fll) into the cornea with a
33 gauge needle. Corneal transfection efficiency by naked
plasmid of pGFP or placZ exceeded 70% as gauged by flow
cytometry and X gal staining. Tail vein injection of clodronate
liposomes (200 fll) and intraperitoneal injection of anti-Gr-1
antibody (200 flg; eBioscience) were performed on each of
the two days before and immediately after corneal injection of
pshRNA sflt-1 injection to deplete peripheral monocytes/
macrophages and neutrophils.
All, C57Bl/6J, corn!, Ifng-1-, ROSA26R (Gt(ROSA) 26
Sormzsor/J) lacZ reporter (The Jackson Laboratory), Vegfb_;_
(The Jackson Laboratory), and Balb/c mice (Harlan Laboratories) were used. Ifnarl-1-, Pax6+1-, Pax6+1+, and Plgf_;_
mice have been previously described (Muller, U. eta!., Science 264:1918, 1994; Quinn eta!., Genes Dev 10:435, 1996;
Carmeliet eta!., Nat. Med. 7:575, 2001). flt-1 1oxP!loxP mice,
generated and characterized by Genentech, are described
elsewhere. Dolphin, dugong, elephant, human, manatee, and
whale eyes were collected in accordance with applicable
regulations. Experiments were approved by institutional
review boards and conformed to the Association for Research
in Vision and Ophthalmology Statement on Animal Research.
Hypoxia was induced by placing C57Bl/6J mice into 8%
0 2 PEGASS chambers (Columbus Instruments) for 24 hours.
siRNA expression cassettes (SECs) were developed by in
vitro amplification by PCR. Exemplary siRNA sequences
include:

32

levamisole (Vector Laboratories). Immunolocalization was
performed with rabbit antibody against the unique carboxylterminus of sflt-1 (1:1000; Orecchia eta!., J. Cell Sci. 116:
3479, 2003), rabbit antibody against the unique carboxyl5 terminus of mbflt-1 (1:1000; clone C-17, Santa Cruz
Biotechnology), goat antibody against mouse VEGF-A
(1:200; R&D Systems), goat antibody against human vascular cell adhesion molecule- I (1: 100; Santa Cruz Biotechnology), rabbit antibody against Cre recombinase (1:5,000;
10 EMD/Novagen) using biotin-streptavidin-horseradish peroxidase, alkaline phosphatase, or immunofluorescent methods using FITC- and PE-conjugated secondary antibodies
(Vector Laboratories). Counter-stain was obtained with Mayer's hematoxylin (Lillie's Modified, Dako ), Nuclear FastRed
15 (Vector Laboratories), or DAPI (1:25,000; Molecular
Probes). Specificity was assessed by staining with control
isotype non-immune IgG, omitting primary antibody, or preadsorbing the primary antibody with a ten-fold molar excess
of the immunizing peptide.
In situ hybridization was carried out on formaldehyde fixed
20
cryosections as previously described. Digoxigenin (DIG)labeled sense and anti-sense riboprobes were transcribed
from mouse sflt-1 and VEGF -A cDNAs using the DIG RNAlabeling kit (Boehringer-Mannheim). The sflt-1 probe corre25 sponded to the divergence site of sflt-1 as previously reported
6. DIG-labeled probes were hybridized, slides were washed
under high-stringency conditions, incubated with alkaline
phosphatase-conjugated anti-DIG antibody (1:2000; Boehringer-Mannheim), and stained with NBT/BCIP (Boe30 hringer-Mannheim).
Cell permeable enzymatically active Cre recombinase
(NLS-Cre) or NLS-~-galactosidase (Hare! eta!., Mol. Bioi.
Cell. 14:4387, 2003), both containing a 6-His tag (SEQ ID
NO: 15 and an SV40 derived nuclear localization signal, were
35 dissolved in PBS (0.6 mg/ml) and dropped on to the surface of
the cornea at the rate of 1 fll/min for 5 min.
Recombinant sflt-1/Fc or control isotype IgG 1 -Fe were
(SEQ ID NO, 1)
AAACAACCACAAAAUACAACA
injected (5 f.tg/2 fll) into the corneas offellow eyes of corn! (at
2 and 3 weeks of age) and Pax6+1- (at 6 and 7 weeks of age)
(SEQ ID NO, 2)
AATGATTGTACCACACAAAGT
40 mice and morphometric measurements of vascularized area
(SEQ ID NO, 3)
TCTCGGATCTCCAAATTTA
on corneal flat mounts were performed, as previously
reported (Ambati eta!., Invest. Ophthalmol. Vis. Sci. 44:590,
(SEQ ID NO, 4)
AAAGGCTGTTTTCTCTCGGAT
2003; Ambati eta!., Cornea 22:465, 2003), at 4 (corn!) and 8
(Pax6+1-) weeks of age.
(SEQ ID NO, 5)
AAAAGCACAAGGAATGATTGT
Enzyme-linked immunosorbent assays (ELISAs) were
45
(SEQ ID NO, 6)
AAAGGCCATTTTCTCTCGGAT
used according to the manufacturer's instructions to quantify
sflt-1 (Quantikine, R&D Systems) and free VEGF-A
(SEQ ID NO, 7)
AAAAGCAGGAGGAATGATTGT
(RELIDA, RELIATech GmbH). Measurements were normalized to total protein (Bio-Rad). Immunoblotting was perIt is understood that the present methods and compositions
encompass the complement sequence of any of the above so formed with rabbit antibody against the amino-terminus of
flt-1 (1: 1,000; Angiobio ), rabbit antibodies against the unique
identified sequences. The invention also encompasses
sequences where "U" (uracil) is substituted for "T" (thymcarboxyl-terminus of sflt-1 (1: 100 or 1: 1,000), goat antibody
against mouse VEGF -A (1: 1,000; R&D Systems), rabbit antiine).
Multiple sequences were screened to identify the best tarbody against mouse VEGFR-2 (1:1,000; clone T014), or rabgets for mbflt-1 (e.g., AAACAACCACAAAAUACAACA 55 bit antibody against Cre recombinase (1: 10,000), and loading
(SEQ ID NO:l)) and sflt-1 (e.g., AAUGAUUGUACCACAwas assessed with rabbit antibody against human GAPDH
CAAAGU (SEQ ID N0:13); and UCUCGGAUCUCCA(1 :2,000; Abeam). Mouse cornea lysates were immunoprecipitated with goat antibody against mouse VEGF-A (2
AAUUUA (SEQ ID N0:14)), which were ligated into the
pSEC Neo vector. Plasmids were prepared (Plasmid Mini
f.tg/ml, R&D Systems) immobilized to protein G-agarose,
Prep kit, Eppendorf) and sequenced to confirm the in-frame 60 subjected to SDS-PAGE, and immunoblotted with biotinysequence of the inserts. psflt-1 * was generated by site
lated goat antibody against the amino-terminus of mouse flt-1
directed mutagenesis (Stratagene) of 2278-AATGATTG(1:1,000, R&D Systems).
TACCACACAAAGT (SEQ ID N0:8) in psflt-1 to AACTotal mouse cornea RNA was prepared (RNAqueous,
Ambion) and eDNA was synthesized by reverse transcription
GACTGCACAACTCAGAGC (SEQ ID N0:9).
Deparaffinized sections were incubated with serum-free 65 (TaqMan, Applied Biosystems) and analyzed by real-time
protein block (Dako or Biogenex). Endogenous peroxidase
quantitative polymerase chain reaction (ABI 7000, Applied
and alkaline phosphatase were quenched with H 2 0 2 and
Biosystems ). The primers for sflt-1 were: forward 5'-AGGT-
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GAGCACTGCGGCA-3' (SEQ ID NO:lO), reverse 5'-ATFurther, the corneal vascularization induced by sflt-1
shRNA was not due to inflammation. Mice eyes were sysGAGTCCTTTAATGTTTGAC-3' (SEQ ID NO:ll). The
temically depleted of monocytes/macrophages and neutroprimers for VEGF -A were described in Zhang eta! (Biochem.
phils by injection of clodronate liposomes and anti-Gr-1 antiBiophys. Res. Commun. 292:860, 2002). FAM (6-carboxyfluorescein)-labeled probes (Maxim Biotech) were used as 5 body. Flow cytometry reveals the monocyte/macrophage and
neutrophil fractions of peripheral blood leukocytes, normaltarget hybridization probes. sflt-1 and Vegfa expression were
ized to control levels, were markedly suppressed by clodrquantified and normalized to glyceraldehyde-3-phosphate
onate liposomes and anti-Gr-1 antibody injection compared
dehydrogenase (Gapdh) or ISS rRNA levels by polymerase
to controls (PBS-liposomes and non-immune rat IgG, respecchain reaction with reverse transcription (RT-PCR) using
10 tively) 3 days after initial injection. *P<0.05 compared to
TaqMan gene expression assays (Applied Biosystems).
controls. In addition, pshRNA-sflt-1 did not elevate VEGF -A
Suspensions of cells isolated from mouse cornea by incumRNA levels compared to pshRNA-mbflt-1 or control uninbation with collagenase D (20 U/ml; Roche Diagnostics) and
jected corneas. Individual VEGF-A isoform levels measured
keratanase (5 U/ml; Sigma-Aldrich) treatment were incuby real time RT-PCR 2 days after injection were divided by
bated in Fe block (0.5 mg/ml; BD Pharmingen) for 15 min on 15 GAPDH levels and normalized to control levels. No pairwise
differences were statistically significant by Bonferroni corice. GFP expression was quantified using Alexa Fluor 488rected Maun Whitney U test.
conjugated rabbit antibody against GFP (1:500; Molecular
The present data indicate that corneal vascularization
Probes). Cells were stained after fixation with 4% paraforminduced by sflt-1 shRNA was specifically due to mRNA
aldehyde and permeabilization with 1% Triton X -100 (Sigma
knockdown because p shRNA-sflt-1, targeted against a difAldrich) and were subjected to FACS analysis (FACSCalibur, 20 ferent sequence than by2 pshRNA-sflt-1, also induced corneal
BD Biosciences). Monocytes/macrophages (CDllb+
vascularization. In addition, the present data indicate that
CD115+F4/80+) and neutrophils (CD11b+F4/80- Gr-1+), in
exogenous VEGF -A induces corneal vascularization by overcells isolated from cardiac blood after erythrocyte hemolysis
whelming endogenous sflt-1. Recombinant mouse VEGFwith lysis buffer (eBioscience), were gated by FITC-conjuA164 injection induces CV in a dose-dependent mauner and
gated rat antibody against mouse CDllb (1:100; eBio- 25 is blocked by co-administration (5 flg) of recombinant sflt-1/
Fe but not isotype control IgGl-Fc.
science), RPE-Cy5-conjugated rat antibody against mouse
The present studies further found that mbflt-1 expressed in
F4/80 (1:10; Serotec), PE-conjugated rat antibody against
the Manatee cornea was inhibited by the immunizing peptide
mouse CD115 (1:1,000; eBioscience), and Alexa Fluor 647but not by an unrelated, negative-control peptide.
conjugated rat antibody against mouse Gr-1 (1: 100; eBioIn addition, naked plasmids are able to transfect mouse
30
science).
corneas in vivo. Flow cytometry data reveal that greater than
Cultured mouse corneal epithelial cells were maintained in
70% of corneal cells express GFP 1 day after injection of
EMEM supplemented with 10% FCS, 1% glutamine, and
pGFP as compared to pNull.
antibiotics at 37° C. under 5% C0 2 . Secreted sflt-1 levels in
SiRNA Design and Synthesis: siRNAs against sFLT
the supernatant were measured by ELISA (R&D Systems) at
unique sequence (differences in bold; 3rd sequence is identi0, 8 and 24 h after serum starvation.
35
cal):
Differences in incidence ofCV and mean levels of protein,
mRNA, and CV area were compared with two-tailed Fisher's
exact test and Mann Whitney U test with Bonferroni correcSEQ
SEQ
tion for multiple comparisons, respectively. P values<0.05
Human
ID
Mouse
ID
were considered significant. Data are presented as 40
mean±s.e.m.
AAAGGCTGTTTTCTCTCGGAT
4 AAAGGCCATTTTCTCTCGGAT 6
As previously noted, specificity of sflt-1 immunolocalization in mouse cornea was inhibited by the immunizing pepAAAAGCACAAGGAATGATTGT
5 AAAAGCAGGAGGAATGATTGT 7
tide but not by an unrelated, negative-control peptide. No
staining was observed when anti-sflt-1 antibody was replaced 45 AATGATTGTACCACACAAAGT 2 AATGATTGTACCACACAAAGT 2
with isotype control IgG or when it was omitted.
Additional studies showed that sflt-1 was present extracelProvided herein are unique homologous siRNA against the
C-terminal tail of sVEGFR 1 that suppress its secretion in
lularly in vivo and in vitro. The pattern of sflt-1 immunostainvitro. HUVEC cells at 50% confluency were transfected with
ing is diffuse and extends beyond cell borders in the superficiallayers of mouse corneal epithelium, and appears external 50 siRNAs against sVEGFR 1 (3 separate sequences, with high
homology for mouse and human sVEGFR 1 targeting the
to cytoplasm and in intercellular spaces in the deeper layers.
unique C-terminal sequence) and an siRNA against GAD PH
Data generated from ELISA experiments demonstrated that
and incubated for 5 days. Culture medium was collected at 1,
mouse corneal epithelial cells constitutively secrete sflt-1.
3, and 5 days for sVEGFR 1 expression assay by ELISA
Further, VEGF -A produced by the cornea co localized with
sflt-1 because immunoreactivities of sflt-1 and VEGF -A were 55 (R&D). siRNA-sVEGFR 1 sequence (SEQ ID N0:2) suppressed the regular increase in sVEGFR 1 expression by
identified as colocalizing in the mouse cornea. Moreover,
64.0% over 5 days.
neutralizing flt-1 protein was capable of abolishing corneal
As shown in FIG. 3, panel G, expression of sVEGR 1 is
avascularity. Corneal injection of anti-fit-! neutralizing antidecreased by siRNA sequence provided in SEQ ID N0:2.
body (nAb) but not isotype control IgG injection elicits invaIntracorneal delivery of this siRNA down-regulates unique
sionofCD31 + LYVE-1-blood vessels into cornea of mice 14 6 C-terminal sequence and VEGF -binding domains of
days after injection. Western blots subsequently showed a
sVEGFR-1. Intrastromal delivery of plasmid expressing
shift in VEGF-A from bound to free form.
siRNA against the uniquely identical target sequence of
In addition, neutralizing flt-1 gene expression abolished
mouse and human sVEGFR 1 into the cornea knocks down
corneal avascularity. pCre but not pNull induces corneal vasexpression of the unique c-terminal 96 nucleotide sequence
cularization in flt-] 10xP!loxP mice. After injection, Cre is 65 of sVEGFR 1 within 2 days. Further, expression of domains
expressed and sflt-1 expression is reduced compared to pNull
2-3, the VEGF-binding domains of sVEGFR 1 is also
knocked down. FIG. 3, panel H shows suppression of unique
injection.

°
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tail of sFLT by siRNA targeting (middle lane). FIG. 3, panel
I shows suppression of mRNA of VEGF binding domains
(553 bp) ofsFLT by siRNA targeting unique tail. Expression
of 18sRNA control (315 bp) is unaffected. Further, FIG. 3,
panel J shows that siRNA-sFLT decreases VEGF bound to
sFLT and increases free VEGF in cornea. Mouse corneas
were subjected to immunoprecipitation by antibody to sFLT
unique tail, then underwent Western blot for VEGF (band
visible at 25 kD). Lanes 1 and 2 are control mouse cornea: 1
is supernatant fraction, 2 is immunoprecipitate. Lanes 3 and 4
are from mouse corneas treated with siRNA-sFLT: 3 is supernatant; 4 is immunoprecipitate. These data demonstrate that
siRNA knocking down sFLT frees VEGF from sFLT sequestration.
The inventors have also demonstrated that, while siRNAsFLT breaches corneal avascularity, it can be restored by
co-delivery of translationally silent mutant of sVEGFR 1.
Intrastromal delivery of plasmid expressing siRNA against
the uniquely identical target sequence of mouse and human
sVEGFR -1 into the cornea knocks down sVEGFR 1 expression within 2 days and stimulates blood vessel formation into
the cornea that is spatially correlated with the injection track.
In addition, mouse corneas 14 days post-injection with
pSEC-siRNA-sVEGFR1 (SEQ ID N0:2) show neovascularization spatially correlated with the injection track. Further,
generation of translationally silent mutant of sVEGFR 1 was
performed by substituting nucleotides 61-81 of this 96 nucleotide sequence (or 2278-2298 of the sFLT gene (sFLT=1st 6
domains of FLT +unique tail in lieu of domain 7 of FLT)
which normally codes for: AAT GAT TGT ACC ACA CAA
AGT (SEQ ID NO: 2) (amino acids=NDCTTQS; SEQ ID
NO: 12). The alternate (mutant) sequence to be substituted for
this is: AAC GAC TGC ACA ACT CAG AGC (SEQ ID NO:
9). Cotransfection of plasmid expressing this mutant sFLT
along with a plasmid expressing siRNA against normal sFLT
resulted in restoration of corneal sFLT expression and normal
corneal avascularity. Moreover, co-injection of plasmids
expressing siRNA-sFLT and translationally silent mutant of
sFLT theoretically resistant to that siRNA shows expression
of unique tail of sFLT at 2 days after injection.
The present studies have determined that sVEGFR 1 is
highly expressed in normal human and mouse corneal epithelium and to a lesser degree in corneal keratocytes, and that

there is a preferential gradient of sVEGFR 1 in peripheral
limbal cornea relative to sclera which would theoretically
contribute to the limbal avascular barrier. Further, the present
data indicates that sVEGFR 1 and VEGF which is normally
bound to sVEGFR 1 is decreased in neovascularized human
corneas thus identifying sVEGFR 1 as a mediator of corneal
avascularity.
Accordingly, provided herein are a series of nucleic acid
molecules developed to down-regulate expression of
sVEGFR 1 by nucleic acid interference. The unique C-terminal tail of sVEGFR 1 was specifically targeted using a target
sequence that is uniquely identical in the mouse and human
gene. Transcriptional disruption of this tail also down-regulates the mRNA transcript of domains 2-3 ofsVEGFR 1, its
VEGF -binding domains, demonstrating knockdown of this
gene. Delivery of a naked plasmid into the mouse cornea
breaches corneal avascularity. This effect is reversed by delivery of a plasmid expressing a translationally silent mutant of
sVEGFR 1. Further, corneal avascularity was not affected by
an siRNA which down-regulates pigment epithelial derived
factor.
The selection process for siRNA screening relied on
homology of target sequence between the mouse and human
VEGF gene because such homology reflects evolutionary
conservation which in turn likely indicates a target of import.
The examples set forth above are provided to give those of
ordinary skill in the art a complete disclosure and description
of how to make and use the embodiments of the devices,
systems and methods of the invention, and are not intended to
limit the scope of what the inventors regard as their invention.
Modifications of the above-described modes for carrying out
the invention that are obvious to persons of skill in the art are
intended to be within the scope of the following claims. All
patents and publications mentioned in the specification are
indicative of the levels of skill of those skilled in the art to
which the invention pertains. All references cited in this disclosure are incorporated by reference to the same extent as if
each reference had been incorporated by reference in its
entirety individually.
A number of embodiments of the invention have been
described. Nevertheless, it will be understood that various
modifications may be made without departing from the spirit
and scope of the invention. Accordingly, other embodiments
are within the scope of the following claims.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 15
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 1
LENGTH, 21
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 1
aaacaaccac aaaauacaac a

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 2
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

21

US 9,198,981 B2
37

38
-continued

<400> SEQUENCE, 2
aatgattgta ccacacaaag t

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 3
LENGTH, 19
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 3
tctcggatct ccaaattta

<210>
<211>
<212>
<213>
<220>
<223>

19

SEQ ID NO 4
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 4
aaaggctgtt ttctctcgga t

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 5
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 5
aaaagcacaa ggaatgattg t

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 6
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE,
aaaggccatt ttctctcgga t

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 7
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 7
aaaagcagga ggaatgattg t

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 8
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

21
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-continued

<400> SEQUENCE,

8

aatgattgta ccacacaaag t

21

<210> SEQ ID NO 9
<211> LENGTH, 21
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic
oligonucleotide
<400> SEQUENCE,

9

aacgactgca caactcagag c

21

<210> SEQ ID NO 10
<211> LENGTH, 17
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic
primer
<400> SEQUENCE,

10

aggtgagcac tgcggca

17

<210> SEQ ID NO 11
<211> LENGTH, 21
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic
primer
<400> SEQUENCE,

11

atgagtcctt taatgtttga c

21

<210> SEQ ID NO 12
<211> LENGTH, 7
<212> TYPE, PRT
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic
peptide
<400> SEQUENCE,

12

Asn Asp Cys Thr Thr Gln Ser
1
5

<210> SEQ ID NO 13
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic
oligonucleotide
<400> SEQUENCE,

13

aaugauugua ccacacaaag u

<210> SEQ ID NO 14
<211> LENGTH, 19
<212> TYPE, RNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic
oligonucleotide

21
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42
-continued

<400> SEQUENCE, 14
ucucggaucu ccaaauuua

<210>
<211>
<212>
<213>
<220>
<223>

19

SEQ ID NO 15
LENGTH,
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
6x His tag

<400> SEQUENCE, 15
His His His His His His
1

5

What is claimed is:
1. A method of treating a condition associated with
decreased vascularity in a subject, the method comprising
administering to a subject in need thereof having the condition associated with decreased vascularity a compound that
increases the bioavailability or biological activity of VEGF
by reducing the bioavailability or biological activity of a
VEGF inactivating agent, and wherein the administering is
sufficient to treat the condition in the subject by increasing
vascularity, wherein the condition is selected from the group
consisting of preeclampsia, systemic hypertension, cerebrovascular disorders, cardiovascular disorders, peripheral
vascular disease, vascular regeneration/recovery, and wound
healing disorders and wherein the VEGF inactivating agent is
fms-like tyrosine kinase is soluble flt-1 (sflt-1) or membrane
bound flt-1 (mbflt-1 ), and wherein the compound is a nucleic
acid molecule.
2. The method of claim 1, wherein the VEGF is selected
from the group consisting ofVEGF-A, VEGF-B, VEGF-C
andVEGF-D.
3. The method of claim 1, wherein the compound comprises a double stranded nucleic acid molecule having one
strand that is at least 95% complementary to at least a portion
of a nucleic acid sequence encoding the agent.
4. The method of claim 3, wherein the nucleic acid molecule comprises an interfering RNA molecule.
5. The method of claim 4, wherein the interfering RNA
molecule is selected from the group consisting of shRNA,
siRNA and miRNA.
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6. The method of claim 4, wherein the interfering RNA is
10 to 40 nucleotides in length.
7. The method of claim 1, wherein the expression of the
agent is reduced by an inducible excision system.
8. The method of claim 7 wherein the inducible excision
system is ere-lox or FLP/FRT excision system.
9. The method of claim 7, wherein excision is facilitated by
the introduction of exogenous CRE recombinase.
10. The method of claim 9, wherein the introduction is by
the topical application ofNLS-Cre.
11. The method of claim 1, wherein the compound is
administered via a topical, intravenous, oral, or intracanalicular route.
12. The method of claim 1 wherein the condition is preeclampsia.
13. A method of treating preeclampsia in a subject, the
method comprising administering to a subject in need thereof
a compound that increases the bioavailability or biological
activity ofVEGF by reducing the bioavailability or biological
activity of a VEGF inactivating agent, wherein the VEGF
inactivating agent is fms-like tyrosine kinase is soluble flt-1
(sflt-1) or membrane bound flt-1 (mbflt-1 ), wherein the compound is a nucleic acid molecule and wherein the nucleic acid
molecule is administered in an amount that is sufficient to
increase vascularity in the subject.

* * * * *

